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“There is a theory which states that if ever anybody discovers exactly what the Universe is for 
and why it is here, it will instantly disappear and be replaced by something even more bizarre 
and inexplicable. There is another theory which states that this has already happened.” 
 
(Douglas Adams) 
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1 INTRODUCTION 
1.1 Nuclear  Receptors 
 
Nuclear receptors are ligand-inducible transcription factors that modulate gene expression in 
response to a wide range of developmental, physiological, and environmental cues. They are 
involved in numerous processes like growth, cell differentiation, proliferation, homeostasis 
and apoptosis. In a signal transduction cross-talk, they regulate the activities of major 
signaling cascades. Ligands for nuclear receptors are small lipophilic molecules such as 
steroid and thyroid hormones or the active forms of vitamin A (retinoids) and vitamin D. 
Recently, it was shown that products of the lipid metabolism, such as fatty acids, 
prostaglandins, or cholesterol derivatives, can regulate gene expression by binding to nuclear 
receptors. However, for a variety of nuclear receptors ligands still remain to be discovered, 
some of these “orphans” are discussed to act as constitutively activating transcription factors 
without binding of a ligand.  
 
Transcriptional regulation results from binding of nuclear receptors to specific DNA motifs, 
the hormone response elements (HREs), which leads to an activation or suppression of target 
gene expression. Nuclear receptor activity is controlled by three distinct mechanisms, whereas 
induction by a small ligand plays the major role. A further mechanism of activation is the 
covalent posttranslational modification, usually in form of a phosphorylation, acetylation, 
methylation or ubiquitinylation, regulated by events at the cellular membrane or during the 
cell cycle. Protein-protein interactions generally occur through contact with other 
transcription factors including nuclear receptors themselves. All three mechanisms work 
either individually or in concert with each other to modulate a specific signal. In addition, 
some nuclear receptors can also mediate rapid nongenomic effects without changes in gene 
transcription [1]. 
Evolutionary studies of the nuclear receptor subfamily according to Laudet et al. [2] have led 
to a subdivision into seven different classes (0-VI). Different receptor families, denoted by 
their most commonly used trivial names, represent each class. Greek letters identify members 
of these families, the receptor isoforms. A list of selected known mammalian nuclear 
receptors and their respectively ligands is presented in Table 1.1. 
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Class 
 
 
Receptor 
 
 
Ligand 
 
Binding 
 
I 
 
TRα, β (Thyroid Hormone Receptor) 
RARα, β, γ (Retinoic Acid Receptor) 
VDR (Vitamin D Receptor) 
PPARα, β, γ (Peroxisome Proliferator 
Activated Receptor) 
 
 
 
RevErbα, β (Reverse ErbA) 
RZR/RORα, β, γ (Retinoid Z Receptor/ 
Retinoic Acid Related Orphan receptor) 
 
 
thyroid hormone (T3) 
retinoic acid 
1-25(OH)2 vitamin D3 
leukotriene B4, 
eicosanoids, 
thiazolidinediones, 
15-deoxy-12,41-prostaglandine J2, 
polyunsaturated fatty acids 
unknown  
cholesterol? 
 
 
H 
H 
H 
H 
 
 
 
 
M, D 
M, D 
II  RXRα, β, γ (Retinoid X Receptor) 
 
9-cis-retinoic acid  D 
III  GR (Glucocorticoid Receptor) 
AR (Androgen Receptor) 
PR (Progesterone Receptor) 
ERα, β (Estrogene Receptor) 
 
glucocorticoids 
androgens 
progestins 
estradiol 
D 
D 
D 
D 
IV  NGFI-Bα, β, γ (NGF induced clone B) 
 
unknown  M, D, H
V  SF-1/FTZ-F1 (Steroidogenic Factor-1/ 
Fushi Tarazu Factor-1) 
 
oxysterols M 
VI  GCNF (Germ Cell Nuclear Factor) 
 
unknown D 
0  SHP (Small Heterodimeric Partner) 
 
unknown H 
 
Table 1.1: Subfamily classes of mammalian nuclear receptors with a selection of family members and their 
respective ligands. Character of nuclear receptor binding to hormone response elements (HREs) as indicated 
(M: monomer; D: homodimer; H: heterodimer) [2,3]. 
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1.1.1  Structure of Nuclear Receptors 
 
Nuclear receptors exhibit a modular structure with different regions corresponding to 
autonomous functional domains that can be interchanged between related receptors without 
loss of function. A typical nuclear receptor is composed of four domains, a variable NH2-
terminal modulatoric A/B domain, a conserved DNA-binding domain (DBD or region C), a 
linking hinge domain (region D) and a conserved ligand binding domain (LBD or region E). 
Some receptors also contain a COOH-terminal region F of so far unknown function. A 
schematical constitution of nuclear receptors is shown in Fig. 1.2. 
 
 
Fig. 1.2: Schematical construction of a typical nuclear receptor composed of several functional domains: the 
modulatoric A/B region containing the ligand-independent AF-1 (activation function-1)  transactivation domain, 
the conserved DNA binding domain C, the variable hinge region D, the ligand binding domain E containing the 
ligand-dependent transactivation domain AF-2 and region F with unknown function. 
 
 
The modulatoric A/B domain is very variable in length and primary sequence. In many cases 
a transcriptional activation function domain (AF-1) is included, this domain contributes to 
constitutive ligand-independent activation of the receptor, e. g. after phosphorylation of this 
site [4]. In contrast, the AF-2 within the C-terminal ligand binding region is responsible for 
the ligand-dependent transactivation. The strong AF-1 domain within the A/B region of the 
nuclear receptor PPARα is phosphorylated by MAP kinases (mitogen activated protein 
kinases) resulting in an enhanced transcriptional activity [5]. By contrast, the activity of 
PPARγ is decreased after phosphorylation by MAP kinases at the A/B domain [6]. 
Interestingly, this PPARγ modification reduces ligand binding to the receptor, showing that 
ligand binding can also be regulated by intramolecular communication between the 
modulatoric and the ligand-binding domain. The nuclear receptor isoforms that only diverge 
from their A/B regions are often generated from a single gene by alternative splicing or by the 
use of different promoters. This is the case for ROR isoforms α1-α4 which are identical in 
their DBD, hinge region and LBD, but differ in their NH2-terminal regions. Because of their 
different A/B domain constitution, RORα isoforms show promoter as well as cell specific 
activity. Introduction 
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The DNA-binding domain (DBD) enables the receptor to bind to specific response elements 
located in the promoter region of the receptor target genes. The DBD is the most conserved 
domain among the nuclear receptor superfamily. This domain comprises two “zinc fingers” 
that span over 60-70 amino acids, in each zinc finger one zinc ion is coordinated 
tetrahedrically by four cysteines and both zinc finger modules are fold together to form a 
compact (Fig. 1.3). The amino acids that are required for recognition of DNA motifs are 
located at the base of the first zinc finger in a region termed “P box”. Further residues at the 
second zinc finger form the “D box” which is involved in receptor dimerization. The DBD 
forms two α-helices: the first binds to the major groove of the DNA contacting specific bases, 
and the second forms a right angle with the first recognition helix [7-9]. C-terminal to the 
second zinc finger, is the 12-15 amino acids long carboxy-terminal extension (CTE) located, 
embedding the T box (tandem box) that is necessary for receptor dimerization on the DNA 
[10] and the A box (adenine box) that serves for recognition of AT regions within a promoter, 
in case of binding as a monomer [11].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3: DNA binding domain of nuclear receptors. Two zinc fingers are formed by four conserved cysteine 
residues, respectively, that coordinate a zinc ion tetrahedrically. Other conserved residues are designated by the 
corresponding letter abbreviation. Helix 1 contains the P box involved in the recognition of response element. 
Residues in the second zinc finger labeled as D box form the dimerization interface. Helix 1 and helix 2 cross at 
right angles to form the core of the DBD that recognizes a hemi-site of the response element [12]. 
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The linking hinge region is weakly conserved among the nuclear receptors. It serves as a 
rotating and arranging hinge between the DBD and the ligand binding domain (LBD), 
facilitating nuclear receptors to bind as homo- or heterodimers to a repeated nucleotide 
hexamer sequence [13,14]. In many cases it harbors a nuclear localization signal and residues 
that are necessary for interaction with nuclear receptor corepressors [15,16].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4: Schematical drawing of the nuclear receptor ligand-binding domain (LBD). Cylinders represent α–
helices that are numbered from 1 to 12. Left: LBD from the crystal structure of unbound RXRα with helix 12 
positioned outwards. Right: Ligand-bound LBD of RARγ, helix 12 seals the ligand binding pocket as a lid [17].  
 
 
The LBD is formed by 12 conserved α-helical regions numbered from H1 to H12 that are 
folded into three layers. In the central of these three layers a cavity is created, the ligand 
binding pocket, where the ligand is accommodated. This domain is mainly hydrophobic and 
its size varies among the different receptors, thus allowing binding of differently sized 
ligands. Interaction of a ligand within the ligand-binding cavity induces a structural transition 
which triggers a mechanism like a mouse trap: in case of unbound receptor, helix 12 is 
positioned outwards, in the opposite direction of the ligand-binding cavity. A ligand-induced 
reposition leads to a conformation where helix 12 seals the ligand pocket as a lid and thus 
further stabilizes ligand binding by contributing to the hydrophobic trap (Fig. 1.4). These 
conformational changes generate a new surface for the recruitment of coactivators [18] which 
include the p160 family (SRC-1/NCoR1; TIF2/GRIP-1/SRC-2; p/CIP/RAC3/ACTR/AIB-
1/TRAM-1) and p300/CBP [19,20]. These coactivators, which have intrinsic acetyltransferase 
activity, recruit other large complexes with ATP-dependent histone remodeling, histone Introduction 
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acetyltransferase (PCAF) [21,22], histone methyltransferase (CARM1/PRMT1) [22,23] and 
histone kinase activities [24]. These complexes decondense chromatine through histone 
remodeling and covalent modifications in order to promote gene expression by binding to the 
receptor response elements embedded in the target gene promoter. For the most nuclear 
receptors recruitment of an additional complex is required (variously termed TRAP, DRIP or 
SMCC) to facilitate the entry of transcription machinery (RNA polymerase II and the general 
transcription factors) to the preinitiation complex [25,26]. 
 
1.1.2  Hormone Response Elements (HREs) 
 
Nuclear receptors regulate gene transcription by binding to specific DNA sequences, known 
as hormone response elements or HREs, in the 5´-flanking regulatory region of a target gene. 
The analysis of a large number of natural occurring as well as synthetic HREs revealed a 
sequence of 6 base pairs as core recognition motif. The responsive elements consist in the 
nucleotide hexamer AG(G/T)TCA, and AGAACA for steroid receptors, respectively. These 
motifs represent idealized sequences, natural occurring HREs can show significant variation 
from that consensus. Although some monomeric receptors can bind to a single hexamer, most 
receptors bind as homo- or heterodimers to HREs composed of two core hexameric motifs. 
Steroid receptors almost exclusively bind as homodimers to the HREs. Two steroid hormone 
receptor monomers bind cooperatively to their response elements, dimerization interfaces 
have been identified both in the LBD and in the DBD. Other nuclear receptors use similar 
dimer interfaces because the corresponding residues are highly conserved in different 
receptors. Although several nonsteroidal nuclear receptors also bind DNA as homodimers, 
most nonsteroidal receptors bind preferentially as heterodimers. In this case, the Retinoid X 
Receptor (RXR) is the promiscuous partner for different receptors [27-29]. Typical 
heterodimeric receptors such as the TR, RAR or VDR can also bind as homodimers to their 
response elements, but heterodimerization with RXR strongly increases the efficiency of 
DNA binding and thus transcriptional activity. In addition, some receptors can bind as 
monomers, homodimers or heterodimers to different response elements. For dimeric HREs, 
the half-sites can be configured as palindromes, inverted palindromes or direct repeats (Fig. 
1.5). Palindromic or inverted palindromic DNA repeats impose a symmetrical head-to-head 
arrangement of the DBDs making analogous contacts with one half-site. Direct repeats consist 
in two consensus motifs that head towards the same direction, connected by a linker of one to Introduction 
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six nucleotides (DR-1 to DR-6). In the case of binding as a monomer, a 5-6 bp long A/T-rich 
sequence precedes the hexamer [30]. 
 
 
Fig. 1.5: Binding of receptors to the hormone response elements (HREs). Receptors can bind as monomers, 
homodimers or RXR heterodimers to DNA. Nuclear receptor binding sites are composed of one or two half-core 
motifs, generally AGGTCA or a close variant that could be preceded by a 5´-flanking A/T-rich sequence. Half-
core sequences in dimeric sites can be arranged as palindromes, inverted palindromes or direct repeats [3,12]. 
 
 
1.1.3  Regulation of Nuclear Receptor Activity 
 
The steroid hormone receptors, such as the estrogen (ER), androgen (AR), progesterone (PR) 
or glucocorticoid (GR) receptors, are associated to chaperone complexes and thus held in the 
cytoplasm. Binding of a ligand acts as an on-switch resulting in release from their chaperone 
complex, subsequent dimerization, entrance into the nucleus and the binding to their hormone 
response elements in the promoter region of the target genes. In contrast, the receptors for 
non-steroidal hormones such as the vitamin D (VDR), retinoic acid (RAR) and peroxisome 
proliferator-activated (PPAR) receptors are preliminary found in the nucleus and bound to 
their response elements as heterodimers with the Retinoid X Receptor (RXR). They are 
associated with histone deacetylase containing complexes and with corepressors, resulting in 
chromatin compaction and gene-silencing. Upon ligand binding, the nuclear receptor 
corepressor interface is destabilized leading to the dissociation of the corepressors and 
subsequent recruitment of coactivators [18]. The AF-2 domain within the LBD cooperates Introduction 
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with the second activation domain in the N-terminus, the AF-1 domain [31], to associate with 
multiple complexes to alter the chromatin structure surrounding of the target gene promoter 
[32,33]. At the end the transcription machinery is recruited, including RNA polymerase II and 
the general transcription factors (GTF) [34]. Simultaneously, the nuclear receptor and their 
coregulators are subjected to rapid modifications like phosphorylation, acetylation, 
methylation, ubiquitinylation and degradation by the proteasome, controlling transcriptional 
activation in a combinatorial, coordinated and sequential manner [35].  
 
Recruitment of coregulators 
Following the activation signal, nuclear receptors bound to their response elements, initiate an 
ordered and coordinated recruitment of a series of coactivator complexes. Five major classes 
of coactivators have been identified: (i) members of the p160 subfamily (SRC-1/N-CoR1, 
SRC-2/GRIP-2/TIF-2, SRC-3/ACTR/AIB1/p/CIP/RAC3/TRAM-1) [36] that serve as 
adapters recruiting other complexes, (ii) histone acetyltransferases (HATs), such as CBP/p300 
[37], (iii) histone arginine methyltransferases (HMTs) [38], (iv) nucleosome remodeling 
complexes [21] and (v) the multisubunit mediator complex that acts as bridge between the 
nuclear receptor and the basal transcriptional machinery [39]. The temporal order of 
recruitment of these coactivators with different enzymatic activities is determined, but may 
differ from one target gene to another [40]. 
 
Ubiquitine proteasome pathway 
Classically, the ubiquitine-proteasome pathway targets regulatory proteins for proteolysis. 
Recently it was demonstrated that nuclear receptors as well as coregulators and components 
of the GFT machinery are ubiquitinylated and degraded by the proteasome in response to a 
ligand. Degradation by the ubiquitine-proteasome pathway might provide an efficient 
mechanism for the termination of nuclear receptors interaction with the promoter [41-45]. 
 
Phosphorylation 
Several extracellular signals such as growth factors, insulin, stress, cytokines, or other signals, 
activate cytosolic kinase cascade pathways, ending at different kinases, including MAPKs 
(ERKs, JNKs, p38), protein kinase C, or cyclic AMP-dependent protein kinase, which can 
subsequently enter the nucleus and phosphorylate nuclear receptors. Estradiol and retinoic 
acid signaling for example, leads to the rapid activation of MAPK (ERKs and p38 MAPK) 
which enter the nucleus and phosphorylate the AF-1 domains of ERα and RARγ [46-48]. Introduction 
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PPARγ transcriptional activity is switched off in response to insulin, subsequent to 
phosphorylation by MAPKs. Several effects of nuclear receptor phosphorylation have been 
shown, such as reduction of the ligand-binding affinity through interdomain communication 
between the phosphorylated AF-1 domain and the ligand-binding pocket [6], or the 
degradation of the receptor by the ubiquitine proteasome pathway as it was shown for RARγ 
and PR [46,49,50]. In the case of RevErb, phosphorylation by GSK3β stabilizes against 
degradation by the proteasome. In addition, phosphorylation of several nuclear receptors in 
their DNA binding domain has been shown to switch off their activity by inducing them to 
dissociate from their promoter [47]. The activity of RARs is negatively modulated in response 
to stress upon phosphorylation of the LBD of their RXR heterodimerization partner [51]. It 
has been proposed that this phosphorylation sterically precludes the formation of the surface 
for coactivator recruitment. Thus, phosphorylation in response to extracellular signals seems 
rather to terminate the response to the ligand, ensuring the escape of nuclear receptors from 
the transcription inition complex.  
However, phosphorylation of the N-terminal A/B region of ERα, ERβ, and PPARα by 
MAPKs or Akt helps the recruitment of coactivators, which increases the efficiency of target 
gene expression. RARs, ERα, PPARs and AR have been reported to be phosphorylated by the 
Cdk7/cyclin H/MAT1 (CAK) subcomplex of TFIIH, which is a general transcription factor 
mediating transcription activation and nucleotide excision repair. TFIIH is composed of 9 
subunits, one of them, cdk7, has a cyclin dependent kinase activity. Binding to the promoter 
makes TFIIH able to dock the liganded nuclear receptor that is bound to its response element, 
thereby allowing the recognition of the cdk7 phosphorylation site in the proline-rich motif 
within the AF-1 domain by the cdk7 kinase subunit. Phosphorylation of the N-terminal A/B 
region of the nuclear receptor leads to an increase of ligand-dependent response. 
As shown in Fig. 1.6, the majority of nuclear receptor phosphorylation sites lie within the N-
terminal A/B region. For certain nuclear receptors such as PR, phosphorylation of this region 
is rather complex with at least 13 phosphorylation sites. For others such as RARs or PPARs, 
phosphorylation of this region concerns only one or two residues. VDR is an exception as this 
region is not phosphorylated at all, probably due to its very short length. Most of these sites 
are phosphorylated either “constitutively” or in response to the ligand. Table 1.7 shows an 
overview about the effects of nuclear receptor phosphorylation. 
Moreover, corepressors and coactivators were also shown to be phosphorylated by MAPKs in 
response to steroidal and non-steroidal hormones. Recently it was suggested, that 
phosphorylation of the N-CoR/SMRT corepressors might represent a mark for their Introduction 
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ubiquitinylation and degradation to allow the recruitment of coactivators [52]. Finally, 
histones were found to be targets of the MAPKs. A combinatorial and coordinated model has 
been suggested whereby phosphorylation participates with acetylation, methylation, and 
ubiquitinylation to provide motifs for the recruitment of other chromatin modifying or 
remodeling complexes [53,54]. Introduction 
11 
 
 
Fig. 1.6: Schematical constitution of non-steroid and steroid nuclear receptors with phosphorylation sites and 
corresponding kinases [47]. 
 Introduction 
12 
 
Table 1.7: Overview about phosphorylation sites of nuclear receptors with corresponding kinases and effect of 
phosphorylation on activity. 
Class Receptor  Kinase  Site  Effect 
 
I 
 
RARα1 
 
cdk7/TFIIH 
PKC 
PKA 
 
77 
157 
369 
 
constitutive [55] 
heterodimerization, activation [56] 
enhancing activity? [57] 
  RARγ2  p38 MAPK 
 
cdk7/TFIIH 
PKA 
66 
 
68 
360 
ligand-dependent; degradation by proteasome 
[46] 
constitutive [58] 
unknown function [59] 
 VDR  PKC   
 
PKA 
Casein kinase II 
51 
 
182 
208 
decreased DNA binding affinity, decreased 
basal activity [60] 
suppression of activity [61] 
increased activity [62] 
  PPARα  p38 MAPK 
PKC 
12/21 
129/179 
increased ligand-dependent activation [5,63] 
increased activity [64] 
  PPARγ1  ERK-2, JNK  84  decreased ligand-dependent and basal activity 
[65,66] 
   RevErbα GSK3β  55/59  stabilization against degradation [67] 
 
II 
 
RXRα1 
 
cdk1/cyclin 
JNK 
MEKK4 
 
22 
61/75/87/265 
248/397 
 
constitutive [68] 
no effect on activity [68] 
suppression of activity [69] 
 
III 
 
GR 
 
cdk/cyclin 
JNK 
 
203/211 
246 
 
ligand-dependent activation [70] 
suppression of activity [71] 
 AR  cdk1 
Akt 
p38, JNK 
81/94/308 
210/790 
650 
stabilization? [72,73] 
decreased activity [74] 
nuclear export [75] 
 PR  cdk2 
 
 
ERK 
20/25/81/102/130/ 
162/190/213/400/ 
430/554/676 
294/345 
basal or ligand induced, activation [76,77] 
 
 
nuclear translocation [78] 
  ERα  cdk/cyclin 
 
ERK 
Casein kinase II 
PKA 
Src-Tyr kinase 
104/106 
 
118 
167 
236 
537 
ligand-dependent and independent activation 
[79] 
ligand-independent activation [80] 
ligand-dependent activation [81] 
suppression of dimerization [82] 
constitutive; unknown function [83] Introduction 
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1.2  The Retinoic Acid Related Orphan Receptor (RORα) 
 
The ROR (Retinoic Acid Related Orphan Receptor) subfamily of nuclear receptors is 
represented by the three subtypes RORα, RORβ and RORγ, which are encoded by three 
different genes. They are so-called “orphan” receptors, because up to now it was not possible 
to clearly identify their endogenous ligands. 
 
1.2.1 RORα Isoforms 
 
ROR receptors were identified as a result of different strategies to clone novel members of the 
nuclear receptor subfamily. By performing reverse transcription experiments on RNA isolated 
from human umbilical vein endothelial cells (HUVECs), using primers designed according to 
the conserved amino acid sequences of the zinc finger motifs of nuclear receptors, RORα4 
was the first RORα isoform that was identified. Because of its high sequence homology to the 
Retinoic Acid Receptor it was first denoted as RZR (Retinoic Z Receptor). The denotation 
RORα was established by Giguere et al. who cloned three further isoforms RORα1-RORα3 
from human retina and testis cDNA in 1994. The four isoforms share a common sequence of 
356 amino acids, composed of the DNA binding domain, hinge and the ligand binding 
domain. RORα1-α4 only differ in their N-terminal A/B region because of alternative promoter 
usage and exon splicing. The isoforms display different DNA binding specificities and 
patterns of expression, and therefore regulate different physiological processes and target 
genes. 
By performing Northern Blot analysis, RORα mRNA was detected in many tissues, including 
heart, brain, skin, muscle, lung, spleen, testis, ovary, thymus, and peripheral blood leukocytes 
[84]. Whereas RORα1 and α4 are expressed in most tissues, RORα2 and α3 are exclusively 
detected in testis after sexual maturation. 
It was shown that the extent of RORα expression varies at a consequence of growth 
conditions. Chauvet et al. [85] demonstrated that hypoxia led to an enhanced RORα mRNA 
level in human hepatoma cells (HepG2). Stimulation with IL-1β, TNFα or lipopolysaccharids 
(LPS) increases RORα expression in human aortic smooth muscle cells (hASMC), whereas in 
atherosclerotic plaques, RORα expression is significantly decreased [86]. 
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Fig. 1.8: Schematical constitution of the RORα isoforms. The four isoforms differ in their N-terminal A/B 
region; the DNA binding domain (DBD), hinge and ligand binding domain (LBD) are conserved. Number of 
amino acids for each domain and for the complete proteins is indicated. 
 
 
1.2.2  ROR Response Element (RORE) 
 
In contrast to most nuclear receptors that bind as dimers to the DNA, RORα binds as 
monomer to the half-core site motif (A/G)GGTCA preceded by a 6 bp long A/T–rich 
sequence. Both the DNA binding domain (DBD) and the carboxy-terminal extension (CTE) 
within the hinge domain are required for efficient DNA binding. Moreover, it was 
demonstrated that the A/B region influences binding of receptors in an isoform-specific 
manner. Whereas RORα1 binds to a large subset of response elements, RORα2 recognizes 
ROREs with strict specificity and shows weaker transcriptional activity [87].  
 
 
 
 
 
 
 
 
Fig. 1.9: Monomeric binding of a nuclear receptor to its response element. Monomeric response elements are 
composed of a nucleotide hexamer (A/G)GGTCA that is recognized by the DBD and preceded by an A/T-rich 
sequence recognized by the carboxy-terminal extension (CTE). The modulatoric A/B domain interacts with the 
CTE to facilitate response element binding with isoform-dependent specificity [88]. Introduction 
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1.2.3 RORα Activity 
 
Coactivators and corepressors 
Glucocorticoid receptor-interacting protein (GRIP-1) and peroxisome proliferator-activated 
receptor (PPAR)-binding protein (PBP) were shown to associate with RORα [40]. However, 
in an in vivo system, only GRIP-1 was able to potentiate RORα activity, whereas PBP had 
little or no effect. By the use of a mammalian two-hybrid assay, Lau et al. [89] demonstrated a 
direct interaction of the RORα LBD with the coactivator p300. p300 either functions as bridge 
for the recruitment of other cofactors, or displays histone-acetylase activity. In addition, p300 
is a coactivator of nuclear receptor- and MyoD-mediated transcriptional activation during 
muscle differentiation. 
Harding et al. [90] demonstrated, that RORα interacts with both nuclear receptor corepressor 
(N-CoR) and silencing mediator of retinoid and thyroid receptors (SMRT) in vitro. However, 
when bound to its RORE, the RORα AF-2 seems to abolish binding affinity to these 
corepressors. DNA binding may alter the RORα protein conformation resulting in an 
constitutive active form that behaves like a ligand-bound receptor. The product of the gene 
hairless (hr) also was identified as a repressor protein of RORα.  Hairless also mediates 
transcriptional repression by the unbound thyroid hormone receptor [91]. 
 
Passive repression by RevErbα 
In contrast to RORα, the orphan nuclear receptors RevErbα and RevErbβ function as 
transcriptional repressors [92]. Both RevErbs miss helix 12 and the AF-2 domain which 
probably results in a lack of coactivator recruitment. Their amino acid sequence of the 
carboxy-terminal extension shows high homology to that of the RORα receptor, which leads 
to recognition of the same DNA consensus motifs [93]. RORα and RevErb receptors regulate 
the same target genes, but with opposite effect. A competition between the activator ROR and 
the repressor RevErb has been shown for the human Apo-CIII promoter [94], the enhancer of 
the rat α-fetoprotein gene [95], the IκBα promoter [96,97], the Bmal1 promoter [98], and the 
expression of genes that are necessary for muscle cell differentiation [89,99]. Interestingly, 
even the expression of RevErbα itself underlies the competitive interplay between RORα and 
RevErbα [100-102]. 
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Ligands 
In transient transfection assays, RORα activity depends on the addition of fetal calf serum 
(FCS) to the medium. Therefore, binding of an ubiquitous occurring ligand for RORα was 
postulated. In 1995, melatonin was discussed as the activating serum agent and thus as a 
ligand for RORα and RORβ [103,104]. Moreover, the thiazolidinedione derivative CGP 
52608 was shown to increase RORα activity and for this reason postulated as synthetic RORα 
ligand [104,105]. However, melatonin enhancing activity on RORβ and in vitro binding 
experiments could not be reproduced, and up to now the question on ROR melatonin binding 
still remains to be clarified. Nevertheless, it could be demonstrated that the inhibiting effect of 
melatonin on the 5-lipoxygenase promoter is dependent on the presence of a functional ROR 
response element [106]. 
In contrast, it was suggested that RORα displays constitutive activity without binding of a 
ligand. A homology model of RORα using the closely related TRβ as template, highlighted a 
nonconserved amino acid in helix 11 of RORα (Phe-491) and a short-length helix at the N-
terminus of AF-2. It was hypothesized that these circumstances ensure that AF-2 is locked 
permanently in the holo-conformation described for other ligand-bound receptors and thus 
enabled ligand-independent recruitment of coactivators. Interestingly, mutation of Phe-491 
ablated transcriptional activation and recruitment of coactivators resulting in a decreased 
RORα activity [107]. 
 
 
1.2.4 Physiological  Functions 
 
The ubiquitous expression of RORα suggests that this protein is involved in many 
physiological procedures all over the organism. The physiological functions of RORα can be 
studied in detail with help of the staggerer (sg/sg) mutant mouse, which was first described by 
Sidman et al. in 1962 [108]. These animals suffer from severe neurological dysfunctions, they 
display a staggering gait, mild tremor and a disturbance of equilibrium. More than 50% die 
within the fourth weak after birth. Cerebellar Purkinje cells are reduced in number and size, 
they are generated in a normal number at the embryonic stage, but undergo cell death within 5 
days after birth. At an age of two months, absence of functional RORα protein leads to an up 
to 80% decreased amount of Purkinje cells, and surviving cells demonstrate a progressive 
atrophy of the dendrites [109-113]. RORα has been shown to regulate the gene for Purkinje 
cell specific protein 2 (Pcp2), however, disruption of this gene in mice has not led to the Introduction 
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cerebellar phenotype of the staggerer mouse. Micro-array experiments with cerebellar RNA 
probes of staggerer and normal mice identified several genes that differ in their expression 
[114], but it is not yet clear, which genes under the transcriptional regulation of RORα are 
responsible for the phenotype displayed in the Purkinje cells of the staggerer mutant mouse. 
In 1996 Hamilton et al. could show, that the staggerer phenotype bases on a 122 bp-deletion 
on chromosome 9 within the RORα gene [115]. This mutation shifts the reading frame and 
prevents translation of the RORα LBD due to the generation of a premature in-frame stop 
codon, the resulting truncated RORα protein is not functional. Steinmeyer et al. generated a 
null mutant mice RORα
-/- by disrupting the RORα gene at the level of the second zinc finger. 
Thus, the emerging RORα truncation mutant is not able to bind to response elements on the 
DNA. RORα
-/- mice exhibit very similar disorders to that of the sg/sg mice. 
In addition to the cerebellar phenotype, further studies of the staggerer mutant mouse revealed 
a variety of age-related phenotypes beyond the cerebellum. The staggerer mouse has been 
shown to display abnormalities in the formation and maintenance of the bone tissue. In 
normal animals, RORα gene expression is increased during the osteogenic differentiation of 
mesenchymal stem cells derived from bone marrow. Two genes encoding important proteins 
for bone mineralization and for generation of the extracellular bone matrix, bone 
sialoglycoprotein and osteocalcin, have been shown to be under the transcriptional control of 
RORα [116]. The bones of homozygous staggerer animals are abnormally fine and long, mass 
and density of bones are decreased. Thus, RORα seems to play a pivotal role in modulation 
and maintenance of bone tissue and in osteoporosis.  
Furthermore, the staggerer mutant mouse has been linked with heart disease. Animals fed 
with an atherogenic diet show a decreased HDL (high density lipoprotein) level and develop 
more severe atherosclerosis than wild-type mice [117]. In fact, RORα has been shown to bind 
to the RORE in the promoter of murine Apo-AI and Apo-CIII genes, and thus directly 
regulates their transcription [118]. Apo-AI is the major constituent of HDL, which is 
responsible for the cholesterol transportation. Controversially to the postulated anti-
atherosclerotic effect of RORα, positive regulation of Apo-CIII causes an increased 
triglyceride plasma level by delaying the degradation of triglyceride-rich particles [94], and 
thus an elevated risk for atherosclerotic disease. In addition, cholesterol derivatives were 
found in the RORα ligand binding pocket, confirming the connection between RORα and the 
lipid metabolism [119-121].  
Abnormalities in immune response of staggerer mutant mice were first discovered by 
Trenkner et al. [122], whose studies revealed a delayed thymic development and a defect in Introduction 
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terminating T-cell responses. Moreover, peripheral macrophages of staggerer mice produce an 
abnormally high amount of the pro-inflammatory cytokines IL-1, IL-6 and cyclooxygenase-2 
(COX-2) on TNFα and LPS stimulation [123]. The expression of IL-1, IL-6 and COX-2 is 
controlled by NF-κB, a transcription factor that is inhibited by the binding to the protein 
IκBα, which masks the nuclear localization signals of NF-κB and abides its cytosolic 
habitation. An inflammatory stimulus caused e. g. by TNFα or LPS, evokes the dissociation of 
IκBα. NF-κB translocates into the nucleus and induces the expression of pro-inflammatory 
genes. Consistent to the elevated cytokine levels in staggerer mice, Delerive et al. [96] 
demonstrated that RORα inhibits the NF-κB pathway by the activation of IκBα gene 
expression which directly verified the anti-inflammatory effect of RORα. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.10: Physiological functions of RORα. Major tasks of the nuclear receptor are summarized with the yet 
identified positively or negatively regulated target genes, according to [88]. 
 
 
RORα has a positive influence on development of skeletal and vascular muscles via up-
regulation of MyoD and p300 expression, providing clue to the understanding of the muscular 
atrophy observed in the staggerer mutant. MyoD activates muscle specific gene expression 
and promotes cell-cycle exit after the induction of differentiation [89,124,125]. In staggerer 
mesenteric arteries, the expression of contractile proteins, such as smooth muscle myosin, 
calponin and heavy caldesmon, is significantly decreased. The response to vasodilators and Introduction 
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vasoconstrictors is significantly reduced, ascertaining that RORα is required for a normal 
contractile function of smooth muscle cells [126]. 
RORα also plays an important role in the regulation of circadian rhythmicity within the 
suprachiasmatic nuclei (SCN) (see chapter 1.3). Staggerer mice entrained in light-dark cycles 
show shorter free-running activity period lengths under constant darkness conditions [98]. 
Additionally, it was demonstrated that heterozygous staggerer mutants show a faster 
adaptation to altered light cycles compared to the nonmutant controls [127]. Fig. 1.10 
summarizes the physiological functions of RORα. 
 
 
1.3 Circadian  Rhythmicity 
1.3.1 Core-Clock 
 
Circadian rhythms are daily cycles of physiology and behavior that are driven by an 
endogenous oscillator with a period of approximately (circa-) one day (diem). When subjects 
are temporally isolated, expression of these daily cycles continues (free-runs) with subjective 
day and night defined by the oscillator. The most obvious circadian rhythm is the cycle of 
sleep and wakefulness. In the phase of circadian day, the physiology is dominated by 
catabolic processes to facilitate adjustment to the environment, whereas at night anabolic 
functions of growth, repair and consolidation predominate. For example, in the evening the 
body temperature falls and melatonin is secreted to facilitate sleep. Sleep onset is 
accompanied by increased secretion of growth hormone and prolactin, whereas before dawn, 
circadian activation of the adenocorticotropic system prepares the organism for the physical 
and mental demands of awaking [128]. 
Circadian rhythmicity in mammals is governed substantially by the suprachiasmatic nuclei 
(SCN), paired cell clusters in the anteroventral hypothalamus. Because the periodicity of the 
circadian clock only approximates that of the environment, these clock must be adjusted to a 
precise 24 h-cycle. Circadian oscillators also exist in most peripheral cells and sometimes 
even in cultured cells [129,130]. The peripheral timekeepers are reset by signals from the 
SCN pacemaker [131]. In addition to light signals, which seem to be the predominant 
“Zeitgeber” (time-giver) for synchronization, other cyclic inputs such as temperature, noise or 
social cues may act as entraining agents. Feeding time also seems to influence the phase of 
oscillators in some peripheral tissues but, notably, is ineffective in resetting time in the SCN. Introduction 
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The molecular composition and function of circadian clocks have been subject of intense 
genetic and biochemical investigations. In mammals, in vitro studies have shown that the 
level of Bmal1 protein expression is the central pacemaker of mammalian circadian rhythms. 
Two RORE are located within the Bmal1 promoter. RevErbα, which acts as a transcriptional 
repressor [92,102,132], may be the major circadian regulator of Bmal1 expression. mRNA of 
transactivating ROR is constitutively expressed all over the day and has the potential ability to 
bind to the Bmal1 promoter at all times of the day. It was shown that ROR competes with 
RevErbα for binding to the RORE [132]. When the RevErbα protein level decreases during 
the circadian night, ROR effectively activates Bmal1 transcription, which consequently 
enhances the amplitude of Bmal1 oscillation and generates a robust and stable oscillation of 
the clock. It still is in discussion, whether an endogenous ligand, which remains unidentified 
so far, may modulate the core-clock by binding to the ROR protein. As shown in Fig. 1.11, 
expressed Bmal1 protein dimerizes with Clock and the Bma1-Clock complex activates the 
expression of Per1 and Per2 (period), Cry1 and Cry2 (cryptochrome) and other clock-
controlled genes (CCGs). Per and Cry proteins in turn repress the Bmal1-Clock 
transactivation, which constitutes the major circadian feedback loop [133]. In addition to the 
feedback loop of Per and Cry which repress their own transcription, there are several forward 
and reverse feedback loops in the transcriptional circuits [134,135]. Bmal1 activates the 
expression of RORγ over E-boxes within the RORγ promoter, RORγ in turn activates Bmal1 
expression via ROREs. Bmal1 activates RevErbα transactivation via E-boxes, RevErbα in 
turn represses Bmal1 and its own expression by binding to ROREs. E4bp4 expression also 
underlies the RORα/RevErbα interplay and E4bp4 protein represses Bmal1-Clock 
transactivation through D-boxes, whereas expressed Dbp protein activates through binding to 
D-boxes. 
Gene expression analysis have shown that the mRNA levels of 16 clock and clock-related 
genes have high amplitude circadian oscillations in the central (SCN) and peripheral clock 
tissues. Nine of the analyzed genes participate in circadian regulation of gene expression 
through E-boxes (Per1/2/3, Cry1, Bmal1, Clock, Npas2, Bhlhb2, Bhlhb3) [136-143], two 
through D-boxes (E4bp4, Dbp) [144,145] and five through ROR/ RevErbα response elements 
(ROREs; RORα/β/γ, RevErbα/β) [98,146,147]. Fig. 1.12 shows the expression profiles of 
RORα, RevErbα, Bmal1, Per1, Cry1 and Clock mRNA in the SCN and liver. Wild-type mice 
were held under a schedule of 12 h light followed by 12 h dark (LD 12:12) for a couple of 
days and then set into constant darkness (DD), so-called free running conditions. In the SCN, 
mRNA of activating RORα peaked at Zeitgeber Time (ZT) 8 and was preceded by repressing Introduction 
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RevErbα mRNA that peaked at ZT 4. As a result of activator and repressor interplay, Bmal1 
mRNA increased delayed to that of RORα mRNA. Bmal1 dimerizes with constitutively 
expressed Clock protein and thus activates the transcription of Per and Cry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.11: Model of the core-clock, driven by Bmal1 oscillation. MAPK: mitogen-activated protein kinase, 
CKIε: casein kinase Iε, GSK3β: glycogen synthase kinase-3β [148]. 
 
 
While circadian expression of Per1 and Per2 is controlled preliminary through Clock/Bmal1 
activation of E-boxes, it has been proposed that the Cry1 mRNA is determined by a 
combination of activities from both E-boxes and ROREs [149]. Indeed, Cry1 levels are higher 
in RevErbα mutant liver at the time of RevErbα expression peak and lower in staggerer SCN 
at the time of RORα expression peak [146]. In the liver of wild-type mice, expression profiles 
of these transcription factors are similar, however, RORα mRNA is expressed constitutively 
all over the day. Lack of RORα oscillation and an increased RevErbα expression results in a 
heightened amplitude of Bmal1, Per1 and Cry1 oscillation. In further peripheral tissues such Introduction 
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as heart, stomach, kidney and lung, also a slight oscillation of RORα mRNA was observed 
[127].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.12: Temporal expression profiles of transcription factor mRNA in mice (A) suprachiasmatic nuclei 
(SCN) and (B) liver under constant darkness (DD) conditions according to Ueda et al. [135]. Relative mRNA 
levels under DD conditions of the indicated genes were measured in a quantitative PCR assay. 
 
 
Results from peripheral tissues suggest a model in which RORα would provide continual 
activation to counteract the rhythmic repression of Bmal1 expression by RevErbα. In silico 
studies revealed a simple hypothetic principle that governs the temporal relationships in the 
expression of these transcription factors. In E-box and RORE regulation, the repressor 
precedes the activator, which delays transcriptional activity. In D-box regulation, repressors 
A SCN 
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and activators are nearly antiphasic, generating transcriptional activities with high amplitude 
[135]. 
However, besides the regulation of protein expression level over feedback loops, regulation of 
circadian rhythmicity might be much more complex because additional events like chromatin 
modification, protein phosphorylation or stability probably influence the system. It was 
hypothesized that posttranscriptional as well as posttranslational modifications are needed to 
adjust the timing of the clock to produce a circadian oscillator that takes approximately 24 h 
[150].The importance of distinct core-clock members was investigated with the help of 
knockout mice. Loss of Bmal1 for example, results in an immediate and complete loss of 
circadian rhythmicity in constant darkness [137]. This demonstrates that Bmal1 is a non-
redundant, essential component of the circadian pacemaker. In contrast, RevErbα deficient 
mice show a persistent circadian rhythm, but with a shorter period and impaired stability and 
precision. In these mice, Bmal1 transcript levels are expressed constitutively throughout the 
day. RevErbα deficient mice can perform unusually large phase-advances initiated during the 
second half of subjective night. The new steady-state phase is reached only a few days after 
exposure (Fig. 1.13) [146]. In vitro studies with a constitutively negative form of RORα that 
lacked the LBD and failed to bind coactivators but still could bind to the DNA, resulted in a 
severely dampened circadian rhythm of Bmal1 transcription. Similar results were obtained 
from transfection of RORα RNAi [127]. Homozygous staggerer mice (sg/sg) held under 
constant dark conditions, show a shortened period length of locomotor activity rhythm (sg/sg: 
23.35 +/-0.066 h, wild-type: 23.84 +/- 0.021 h). When the lighting cycle was advanced for 4 
h, heterozygous staggerer mice (+/sg) re-entrained almost completely at the first onset of 
darkness and entrainment was complete after 5 d. In contrast, wild-type mice re-entrained 
progressively over 10 d. When animals were maintained in a short light-dark cycle, LD 6:6, 
the activity of heterozygous (+/sg) was abruptly inhibited by light or became arrhythmic. 
Although RORα seems not to be required for generation of a circadian rhythm, it influences 
the period length and affects the stability of the clock. However, staggerer mice showed 
enhanced adaptability to a phase advance and were more sensitive to photic manipulation 
[127].  Introduction 
24 
 
 
 
 
 
 
 
 
Fig. 1.13: Circadian phenotype of RORα-deficient staggerer mice. (A) Activity records of a wild-type (+/+) 
and a homozygous mutant mice (sg/sg). Light regime: 10 d in LD followed by 13 d in DD. (B) Actograms of a 
wild-type (+/+) and a heterozygous staggerer mouse (+/sg) showing baseline activity and response to a 4 h 
phase advance. The arrow indicates the beginning of phase advance. (C) Actograms of a wild-type and a 
heterozygous staggerer mouse that were subjected to a 6 h light and 6 h dark (6:6) cycle [127].  
 
 
Melatonin 
Ocular light plays a key role in human physiology by transmitting time of day information. 
Production of the pineal gland hormone melatonin is under control of the light-dark cycle, and 
its profile of secretion defines biological night. Receptors for melatonin are highly expressed 
within the SCN [151-153], but the physiological action of melatonin within maintenance of 
the core-clock is poorly understood. Indeed, daily melatonin injections in free-running rats 
resynchronize their locomotor activity to 24 h [154]. It was shown that expression of Per1, 
Cry1 and Bmal1 in the mouse hypophyseal pars tuberalis was dramatically reduced in 
melatonin receptor 1 knockout mice (MT1 ko). In MT2 ko mice, mRNA level of these 
transcription factors were unaffected [155]. Hyperphysiological injections of melatonin at the 
end of a subjective day did not affect RORα mRNA level, whereas RORβ mRNA level was 
slightly increased. Interestingly, the rhythm of RevErbα mRNA expression was phase-
advanced by 1.3 +/- 0.8 h, but without effect on the amplitude [156]. 
 
1.3.2  Phosphorylation of Core-Clock Members 
 
In addition to transcriptional positive and negative feedback loops, further levels of regulation 
operate to establish and maintain circadian rhythms. These include posttranscriptional 
regulation [157,158], posttranslational modifications [159], chromatin-remodeling 
[149,160,161], availability and stability of clock proteins [162,163], and regulation of 
intracellular localization [159,164]. The fine regulation of clock proteins by intracellular 
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signaling plays an essential role in the physiological control and resetting of circadian 
rhythmicity (Fig. 1.11).  
 
Per proteins 
Genetic studies have provided solid evidence for the crucial role played by phosphorylation of 
Period proteins. The gene effected by the tau mutation, which causes a short-period 
phenotype in the Syrian hamster, was identified to encode casein kinase I epsilon (CKIε) 
[165], which was demonstrated to phosphorylate Pers. The short-period phenotype observed 
in  tau hamsters is directly linked to a lower rate of CKI-dependent phosphorylation. 
Intriguingly, a deficiency in Per phosphorylation by CKIε has also been implicated in human 
sleep disorders. Indeed, familiar advanced sleep-phase syndrome (FASPS) has been 
associated with a missense mutation in the human Per2 gene, which leads to a less effectively 
phosphorylated form [166]. CKIε has also been shown to control protein stability and 
subcellular localization of Per [167-169]. CKIε specifically interacts with and phosphorylates 
Per1, Per2 and Per3, and thus regulates each of them differently. CKIε binding domains are 
highly conserved in Per1 and Per2, whereas that of Per3 is divergent resulting in a much 
weaker CKIε binding affinity [163,170]. Interestingly, Per1 and Per2 seem to play a pivotal 
role in circadian rhythmicity, whereas Per3 is dispensable for a functional clock [138,140]. 
CKIε phosphorylation of Per2 and Per3 induces their degradation through the ubiquitine-
proteasome pathway [163,166]. Phosphorylation of Per proteins by CKIε also influences the 
subcellular localization by masking or unmasking their localization sequences. 
The intracellular distribution and posttranslational modifications of Per proteins are also 
influenced by the association of Pers with Crys. The two PAS domains and the C-terminal 
conserved regions of Per are required for Per-Per and Per-Cry dimerization. Per-Cry 
dimerization stabilizes both proteins by preventing their ubiquitinylation-proteasome 
mediated degradation [162].  
 
Cry proteins 
Mammals have two Cry proteins, Cry1 and Cry2 that seem to exert opposite functions within 
the circadian oscillator, because mice lacking Cry1 or Cry2 genes exhibit accelerated or 
delayed free-running periodicity of locomotor activity [171]. Nevertheless, both Cry1 and 
Cry2 are strong repressors of Clock-Bmal1 mediated transcription by direct interaction with 
the Clock-Bmal1 heterodimer in the nucleus [172,173]. In mouse liver, Crys are detected 
mainly in the cytoplasm, where they dimerize with Per proteins and subsequently translocate Introduction 
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to the nucleus. Besides controlling the subcellular distribution of Cry proteins, Pers appear to 
be essential for Cry phosphorylation by CKI. CKIε and Cry do not interact directly, but both 
can bind simultaneously to Per proteins. Thus, Pers seem to act as a bridge, bringing both 
proteins into the same ternary complex, in which CKIε can phosphorylate Crys [174]. 
A recent study reported that MAPK phosphorylates mouse Cry1 (Ser-247) and Cry2 (Ser-
265) and thus reduces Cry repressor activity [175]. MAPK also phosphorylates Ser-557 in 
mouse Cry2, preparing the protein for a further phosphorylation by glycogen synthase kinase-
3 beta (GSK-3β). After phosphorylation by GSK-3β, Cry gets degradated by the ubiquitine-
proteasome pathway. The Ser-557 phosphorylated form accumulates in the liver during the 
night and peaks in parallel with Cry2 protein [176]. Interestingly, GSK-3β exhibits a circadian 
rhythm in its activity with a peak from late night to early morning [177], at the same time 
when Ser-557 of Cry2 is highly phosphorylated. 
 
Clock and Bmal1 proteins 
Bmal1 protein shows circadian oscillation in its phosphorylation status and subcellular 
distribution in mouse liver as well as in the suprachiasmatic nuclei. The phosphorylated form 
of Bmal1 protein is mostly nuclear [159,164,178]. Additionally, Clock-Bmal1 dimerization 
induces Bmal1 phosphorylation and facilitates nuclear localization. Crys are directly involved 
in these posttranslational modification and subcellular distribution, but so far the mechanism 
is poorly understood [179]. Two kinases, CKIε and MAPK have been shown to phosphorylate 
Bmal1 in vitro. MAPK phosphorylates three residues, Ser-527, Thr-534 and Ser-599 [180], 
but the CKIε consensus motif has not yet been identified. A well conserved consensus site for 
CKIε is located within the C-terminal domain of Bmal1 protein. Interestingly, this putative 
motif overlaps in part with a MAPK consensus, suggesting that these two kinases could 
compete to regulate Bmal1 function. Consistent with this idea, MAPK phosphorylation results 
in a decreased Clock-Bmal1 transcription activation, whereas CKIε-mediated phosphorylation 
increases transactivation [174]. In addition, Bmal1 is sumoylated at Lys-259, which is 
induced by Clock protein; the circadian pattern of Bmal1 sumoylation is parallel to its 
activation in the mouse liver [181]. 
Clock protein also contains a well conserved CKI phosphorylation site in its center. However, 
CKIε does not seem to phosphorylate Clock in vitro. In mouse liver, CKIε forms a trimeric 
complex with Per-Cry, which translocates to the nucleus and associates with Clock-Bmal1. 
CKIε might phosphorylate Clock in addition to Bmal1 in this multimeric complex. 
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1.4  Mitogen-Activated Protein Kinases (MAPKs) 
 
Cells respond to extracellular signals by generating intracellular signals and instructions to 
coordinate appropriate responses. Among the pathways often used to transduce extracellular 
signals, are the highly conserved mitogen-activated protein kinase (MAPK) or extracellular 
signal-regulated protein kinase (ERK) cascades. These cascades are found in all eukaryotic 
organisms and consist of a three-kinase module that includes a MAPK, which is activated by 
a MAPK/ERK kinase (MEK), which is in turn activated by a MEK kinase (MEKK) [182-
185]. This cascade is activated by diverse extracellular stimuli and by pro-oncogenic products 
that induce proliferation or enhance differentiation. MAP kinase phosphorylations influence 
processes in the cytoplasm, the nucleus, the cytoskeleton, and the membrane. 
ERK1 and 2 are widely expressed and are involved in the regulation of meiosis, mitosis, and 
postmitotic functions in differentiated cells. Many different stimuli, such as growth factors, 
cytokines, virus infection, ligands for G-protein coupled receptors, transforming agents, and 
carcinogens, activate the ERK1/2 pathways. Most stimuli that activate ERKs convert plasma 
membrane anchored Ras from its GDP-bound state into its GTP bound state. Ras-GTP binds 
directly to the seryl/threonyl kinase Raf, forming a transient membrane-anchoring signal 
[186]. Active Raf phosphorylates the kinase MEK on Ser-218 and Ser-222 [187,188], 
allowing MEK to phosphorylate its only known substrates ERK1 and 2. MEK mutants which 
mimic the effect of phosphorylation of residues 218 and 222 (by substitution of serines with 
either aspartic acids or glutamic acids) have constitutive activity in vitro and are oncogenic in 
vivo [189,190]. Once phosphorylated on Thr-183 and Tyr-185 [191,192], ERK1 and 2 
phosphorylate numerous cytoplasmatic proteins (pp90 ribosomal S6 kinase [RSK], cytosolic 
phospholipase A2, and the EGF receptor [193-195]). In addition, ERKs translocate to the 
nucleus, where they can phosphorylate nuclear receptors like Elk-1, ERα [80], PPARγ [65,66] 
and other transcription factors. 
MAPKs are grouped into subfamilies on the basis of sequence similarity, mechanisms of 
upstream regulation and sensitivity to activation by different MEKs. Ten years ago, only three 
subfamilies were known, ERKs, c-Jun N-terminal kinase/stress activated protein kinase 
(JNK/SAPK) and p38. ERK3 lacks the dual phosphorylation motif and thus probably lies in a 
fourth, uncharacterized pathway [196]. Many MAPKs have been discovered recently, 
including ERK5 [197] and four p38-like kinases namely Mxi2 [198], a truncation form of 
kinase subdomain XI, ERK6 [199], which is 63% identical to p38, SAPK3 [200] and Introduction 
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p38β [201]. Eight additional splice variants of JNK/SAPK were identified within the brain 
[201]. 
As mentioned above, the activation of GSK-3β underlies a circadian rhythmicity which 
contributes to the rhythmic degradation of Cry2 protein. Moreover, RevErbα is also 
phosphorylated by GSK-3β followed by protein degradation, suggesting that the circadian 
oscillation of kinase activity may contribute to the maintenance of the biological clock [202].  
Obrietan et al. [203] were the first who found that in mice maintained in constant darkness, 
levels of the active, phosphorylated form of ERK in the SCN showed significant variation 
across the circadian cycle, with levels being high during the subjective day and low during 
subjective night. When mice are exposed to light pulses during the subjective night, p-ERK is 
rapidly up-regulated in the SCN. Light impulses during the subjective day fails to induce any 
changes in ERK phosphorylation. The levels of p-ERK caused by light pulses during 
subjective night quickly decline on termination of the pulse with levels back at baseline 1 h 
after initiation of the pulse. If the photic stimulation is not terminated and lights are left on, 
elevated levels of p-ERK decline after 90-120 min [204-208]. This finding might suggest that 
the ERK cascade in the SCN is under autoregulatory feedback regulation. It was reported that 
in addition to a circadian rhythm in the total expression of p-ERK, the distribution of intra-
SCN p-ERK is time-dependent regulated. During subjective day, p-ERK is spontaneously 
expressed in the ‘shell’ area of the SCN and during subjective night solely in the mid-caudal 
level of the SCN. Expression by the mid-caudal neurons is dependent on the presence of a 
retinal innervation, as optic enucleation (blinding) ablates this ‘core’ p-ERK formation [209]. 
These findings support the idea of a functional compartmentalization within the SCN clock 
[210]: the ‘core’ area of the SCN is primarily responsible for processing incoming photic 
information, and the ‘shell’ region represents the subpopulation of spontaneously rhythmic 
neurons that, in turn, receive photic information from the ‘core’ neurons. 
The upstream regulation of ERK within the SCN remains to be determined. NMDA receptor 
activation seems to be necessary for photic induction of p-ERK [205]. However, the 
intracellular events linking NMDA receptor activation and ERK phosphorylation are not 
clear. Inhibitors of calcium/calmodulin kinase II (CAMKII) block both light-induced 
behavioral phase shifts [211] and Per1 and Per2 expression [212,213], and suppress photic 
induction of p-ERK [204]. Calcium influx via the NMDA receptor channel therefore may 
activate CAMKII which, in turn, may lead to phosphorylation of ERK [214]. This 
mechanism, however, does not explain the spontaneous rhythm in ERK activation. The 
upstream regulators of ERK, Raf-1 and Ras, oscillate in-phase with p-ERK and p-MEK in the Introduction 
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chick pineal gland, a tissue known to contain an endogenous circadian clock [215]. A recently 
described novel protein inhibitor of Ras activation, the SCN circadian oscillatory protein 
(SCOP), oscillates in the SCN in anti-phase to p-ERK [216]. Overexpression of SCOP 
attenuates up-regulation of p-ERK. Spontaneous expression of SCOP therefore may regulate 
the cyclic expression of p-ERK in the SCN (Fig. 1.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.14: Putative signaling of ERK activation within the SCN. Factors displaying a waveform beside them 
have shown circadian rhythmicity in their expression/activity. The circadian rhythm in p-ERK at constant 
conditions may be due to a fluctuating, calcium-dependent positive drive and an oscillating, SCOP-mediated 
negative drive [206]. 
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2  AIM OF THE PRESENT INVESTIGATION 
 
RORα4 was first identified in 1993 [84], and up to now few is known about the RORα 
signaling pathways and methods of activation or inactivation. In order to perform a detailed 
functional analysis of the nuclear receptor regulation, this investigation starts with the 
establishment of a method for production of pure RORα4 protein in E. coli. The 
overexpression and purification method should be optimized to obtain large amounts of very 
pure RORα4, whose functionality should be confirmed in a DNA binding affinity test. In 
addition to that, an antibody for ROR should be developed that features high sensitivity and 
specificity. Moreover, a method for isolation a pure antibody that could be stored for long-
term usage should be found. 
Subsequently, on the basis of this method and material equipment, studies on RORα4 
phosphorylation came into the focus of interest. Effects of phosphorylation on protein 
function, localization and interaction with the RORα opponent RevErbα were tested. Further 
posttranslational modifications should be examined, including protein cleavage and 
sumoylation.  
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3 MATERIALS  AND  METHODS 
 
All used chemicals and reagents were purchased from Applichem (Darmstadt), Sigma-Aldrich 
(Steinheim), Merck (Darmstadt) or Fluka (Buchs, Switzerland). Kits for DNA and plasmid 
preparation were from Machery-Nagel. Constitution of buffers that is not described here, can 
be found in Sambrook et al. [217].  
 
3.1  Western Blot  
 
For immunochemical detection and identification of proteins, samples were separated 
electrophoretically on a 10% SDS-polyacrylamide gel (electrophoresis buffer: 0.25 M Tris-
HCl, 0.8 M glycine, 0.04 M SDS) and afterwards transferred on a polyvinylidendifluoride 
membrane (PVDF, Millipore) by electroblotting (transfer buffer: 25 mM Tris-HCl, 190 mM 
glycine, 20% methanol). After blocking the membrane surface by gently shaking in 5% low-
fat-milk powder/TBS for 60 min, the blot was incubated with the particular first antibody (e. 
g. mouse anti-ROR) for 90 min. Unbound antibody was washed off from the membrane by 
shaking 3x 10 min in TBS/1% Tween. Subsequently, the blot was incubated with alkaline 
phosphatase conjugated second antibody (e. g. anti-mouse, Sigma) for 90 min, washed 2x 10 
min with TBS and prepared for detection by washing 10 min with TBS/0.1 % NP-40 and 
detection buffer (0.1 M Tris-HCl pH 9.5, 0.1 M NaCl, 0.05 M MgCl2). In a last step, the blot 
was incubated with detection buffer containing nitroblue-tetrazolium chloride (NBT, 
330µg/ml) and 5-bromo-4-chloro-3-indolylphosphate (BCIP, 170 µg/ml) until clear bands 
appeared. The reaction was stopped with TBS/2 mM EDTA. Blots were stored in Milli-Q at 
4°C. Blots were scanned with an AGFA Arcus II Scanner. 
 
3.2 Coomassie  Staining 
 
For the detection of total proteins in a probe separated by SDS-PAGE, staining was performed 
with Coomassie brilliant blue R-250 or G-250 (Biorad). The SDS-polyacrylamide gel was 
incubated in 20% trichloro-acetic acid for 30 min immediately after electrophoresis, then 
washed with Milli-Q and subsequently incubated in Coomassie staining solution (0.1% 
Coomassie R-250/G-250, 50% methanol, 10% acetic acid) for 60 min with gentle shaking. Materials and Methods 
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Destaining of the background was performed by washing with 20% methanol/10% acetic acid 
until clear bands appeared (2-3 h). Gels were scanned with an AGFA Arcus II Scanner. 
 
3.3  Bradford Protein Determination 
 
For Bradford [218] protein concentration determination, a standard concentration series was 
prepared. As standard protein for concentration determination of RORα or RevErbα solutions 
bovine serum albumin (BSA, Sigma) was used, γ-globulin (Sigma) was chosen for antibody 
solutions. 100 µl of the standard concentration series solutions and protein solution were 
applied onto a 96-well plate. 25 µl Bradford-reagent (Sigma) was added to each well, and 
after plate vortexing and incubation for 10 min at room temperature, absorbance at 600 nm 
was determined by a Dynatech MR5000 ELISA Reader. Concentration of protein solutions 
was calculated from linear equation of calibration curve. 
 
3.4  Electrophoretic Mobility Shift Assay (EMSA) 
 
5´-IRDye700 labeled oligonucleotides were purchased from Metabion. The following 
complementary oligonucleotides were annealed to generate double-stranded DNA fragments 
encompassing the ROR response element (RORE, underlined): 
 
RORE-sense 5´-TCGAGTCGTATAACTAGGTCAAGCGCTGGAC-3´; 
RORE-antisense 5´-GTCCAGCGCTTGACCTAGTTATACGACTCGA3´. 
 
The standard 20 µl binding reaction mixture contained 1 mg of purified recombinant RORα4, 
3 µg poly-dA-dT (Amersham), 5 mM DTT, 5% Tween 20, 4 mM EGTA and 1.8 mM Na3VO4 
in Binding Buffer (20 mM HEPES pH 7.5, 1 mM DTT, 150 mM KCl, 1 mM MgCl2, 0.5mM 
EDTA, 0.05g/l BSA, 5% Glycerol). After pre-incubation on ice for 15 min, 0.6 fmol 
IRDye700-RORE was added and preparation was incubated for another 15 min on ice. The 
reaction mixture was loaded on a 4% polyacrylamide gel and the complexes were separated in 
0.5x Tris-borate-EDTA at 4°C. Gels were scanned with an Odyssey infrared imaging system 
(Licor). Specificity of RORα4-DNA and RevErbα-DNA complexes was demonstrated by the 
addition of 2.2 µg anti-RORα antibody or 6 µg anti-RevErbα (US Biological) antibody to the 
binding reaction mixture which caused a complete loss of shifted bands. Materials and Methods 
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3.5  In-Gel Kinase Assay (IGKA) 
 
Preparation of cell lysates. Human polymorphonuclear leucocytes (PMNL) were isolated 
immediately from fresh leukocyte concentrates obtained from healthy donors at St. Markus 
Hospital (Frankfurt, Germany) as described [219]. For incubations, cells were resuspended in 
isotonic PBS containing 1 mg/ml glucose and 1 mM CaCl2 (PGC buffer) and incubated with 
different stimuli such as N-formyl-Met-Leu-Phe (fMLP, 1.5 min; Calbiochem), platelet 
activating factor (PAF, 1.5 min; Calbiochem), O-acetyl 11-keto boswellic acid (AKBA, 1.5 
min), arachidonic acid (AA, 1.5 min; Sigma), ionophore A23187 (Iono, 2 min; Sigma), 
phorbol 12-myristate 13-acetate (PMA, 3 min; Calbiochem), sodium arsenite (SA, 3 min; 
Sigma) and sucrose (3 min; Sigma) at 37°C. Incubations were stopped by addition of ice-cold 
2xSDS-PAGE sample loading buffer and heating at 95°C for 6 minutes.  
Electrophoresis. A Mini-Protean system (Bio-Rad) was used. Aliquots of total cell lysates 
were loaded on a 10% SDS-PAGE gel containing 2-3 mg/ml purified recombinant human 
RORα4 or RevErbα protein, respectively. As positive control a gel polymerized with 500 
µg/ml myelin basic protein was used, a gel without any added protein served as negative 
control. 
In-gel renaturation. After electrophoresis, SDS was removed by washing the gels 5x 10 min 
with buffer A (20% isopropyl alcohol, 50 mM Tris-HCl pH 8.0) and 5x 10 min with buffer B 
(50 mM Tris-HCl pH 8.0, 1 mM DTT). In-gel proteins were denatured by incubation for 60 
min in buffer C (50 mM Tris-HCl pH 8.0, 20 mM DTT, 2 mM EDTA, 6 M guanidine-HCl 
(Sigma)). To renature proteins, gels were washed once for 10 min in buffer D (50 mM Tris-
HCl pH 8.0, 1 mM DTT, 2 mM EDTA, 0.04% Tween 20) followed by overnight incubation 
in 300 ml of the same buffer at 4°C with shaking. 
In-gel phosphorylation. Gels were incubated in kinase buffer (20 mM HEPES pH 7.6, 20 mM 
MgCl2, 25 mM β-glycerolphosphate, 10 mM 4-nitrophenylphosphate, 2 mM DTT, 0.2 mM 
Na3VO4) for 60 min at room temperature and finally incubated in 10 ml kinase buffer 
containing 10 µCi/ml γ-[
32P]-ATP (Amersham) for 60 min at 30°C with shaking. To remove 
unbound γ-[
32P]-ATP, gels were washed in washing buffer (1% sodium pyrophosphate, 5% 
trichloro-acetic acid) for two days with several buffer exchanges, followed by in vacuo-drying 
and incubation on imaging plates for three days. For visualization, imaging plates were 
scanned with a FLA-3000 Scanner (Fuji).  
 Materials and Methods 
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3.6  In Vitro Kinase Assay (IVKA) 
 
Purified recombinant RORα4 (3-7µg) or RevErbα (1 µg) was incubated with activated ERK-2 
MAPK (rat, recombinant; Biomol), PKA (catalytic subunit from bovine heart; Sigma) or p38-
MAPK (GST-fusion, mouse, recombinant; Calbiochem) in kinase buffer (25 mM HEPES, pH 
7.5, 25 mM MgCl2, 25 mM β-glycerolphosphate, 2 mM DTT, 0.1 mM Na3VO4) containing 
ATP (100 µM, Sigma) and γ-[
32P]-ATP (2 µCi/ml; Amersham). The samples were incubated 
at 30°C for 30 min. The reaction was determined by addition of 2x SDS-PAGE loading 
buffer, probes were heated at 95°C for 6 min and separated by SDS-PAGE. Phosphorylated 
RORα4 was visualized by incubation of the dried gel for 24 h on an imaging plate followed 
by scanning with a FLA-3000 Scanner (Fuji).  
 
3.7 Cell  Culture 
 
HeLa, HEK293 and MCF-7 cells were grown at 37°C in a humified atmosphere with 6% CO2 
in Dulbecco´s modified Eagle medium (D-MEM, Gibco) supplemented with 10% (vol/vol) 
fetal calf serum (FCS, Sigma-Aldrich), 100 µg/ml streptomycin and 100 U/ml penicillin 
(PAA Laboratories). For transient transfection, cells were seeded in D-MEM without phenol 
red (Gibco). 
Stripped FCS was prepared by stirring 100 ml heat-inactivated FCS with 2 g charcoal (Sigma-
Aldrich) for 2 h at 4 °C. The suspension was centrifuged at 51,500 g and the clear supernatant 
was frozen at –20°C. Immediately prior use, treated FCS was added to the cell culture 
medium and solution was sterile filtrated (0.45 µM, Roth). 
 
3.8 Transient  Transfection 
 
Transient transfections were performed using the calcium phosphate precipitation method as 
described [217]. 24 h before transfection, cells were seeded in 24-well plates (Greiner bio-
one): HeLa: 4x10
4/well, HEK-293: 10x10
4/well, MCF-7 8x10
4/well in 1 ml D-MEM cell 
culture medium without phenol red (Gibco). 10 µg or 20 µg reporter gene plasmid (400 
ng/well viral promoters or 800 ng/well human promoters, respectively) along with 0.5 µg of 
the internal standard plasmid pCMV-SEAP were diluted with Milli-Q water to 450 µl. After 
addition of 50 µl 2.5 M CaCl2, the solution was dropped slowly into 500 µl 2xHeBS buffer Materials and Methods 
35 
(50 mM HEPES, 28 mM NaCl, 1.5 mM Na2PO4, pH 7.05) during continuous influx of sterile 
air. After a precipitation time of 1 min, 40 µl suspension was pipetted into each well. Cell 
culture medium was changed after 16 h of incubation and stimulating substances were added 
if necessary. Cells were grown for another 24 or 48 h; immediately before reporter gene 
analysis was performed, 33.3 µl cell supernatant was collected for standard determination.  
 
3.9 Reportergene  Assay 
 
3.9.1 Luciferase  Assay 
 
For determination of luciferase activity, cell culture medium was replaced by 100 µl fresh 
phenol red-free D-MEM (Gibco), and 100 µl Steady-Glo reagent (Promega) was added to 
each well. Cell suspensions were transferred from 24 well plate into a 96 well microtiter plate 
(Greiner bio-one) and 15 min after addition of Steady-Glo reagent to the first well, 
measurement of luciferase activity was started by monitoring the light emission in a 
Mikrolumat Plus LB96V EG&G Berthold Luminometer. Luminescence was integrated from 5 
sec for each well. All transfection experiments were performed as triplicates and as mean of 
three independent experiments. 
 
 
Fig. 3.1: Chemiluminescent conversion of luciferin to oxyluciferin, catalyzed by the firefly luciferase enzyme. 
Emitted light was quantified by luminescence measurement. 
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3.9.2 SEAP  Assay 
 
In order to equalize the varying transfection efficiencies, activity of the secreted alkaline 
phosphatase (SEAP) was assayed with the Phospha-Light kit (Tropix) according to the 
manufacturers instructions. For this purpose, 33.3 µl cell supernatant were heated for 30 min 
at 65°C along with 100 µl dilution buffer. 2x 50 µl of this solutions were transferred into a 96 
well microtiter plate (Greiner bio-one), incubated with 50 µl assay buffer for 5 min and 
afterwards 20 min with 50 µl reaction buffer. Signals were detected with a Mikrolumat Plus 
LB96V EG&G Berthold Luminometer which was programmed to integrate light emission for 
1 second. Relative light units (RLU) were calculated as follows: RLU= 
(LUluciferase/LUSEAP)x1000 [LUluciferase: light units of luciferase activity; LUSEAP: light units of 
alkaline phosphatase activity]. 
 
 
 
 
 
 
 
 
Fig. 3.2: Chemiluminescent conversion of CSPD dioxetane catalyzed by the secreted alkaline phosphatase 
enzyme (SEAP). Emitted light was quantified by luminescence measurement. 
 
 
3.10  Analysis of EGFP-RORα4 Subcellular Distribution 
 
For analysis of the intracellular distribution of EGFP-tagged RORα4-WT and mutants, HeLa 
or HEK293 cells were grown on glass cover slips. Cells were transiently transfected by 
calcium phosphate method [217]. 16 h after transfection the medium was changed, and after 
another 24 h cells were fixed with 4% paraformaldehyde in PBS for 10 min. For co-staining 
of the nucleus, cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min and stained 
for 20 min with 1 mM TO-PRO-3 iodide (Molecular Probes) in PBS with 1% BSA. Images 
were taken by confocal laser scan microscopy (Zeiss LSM 510 Meta). 
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3.11  Genetic Engineering and Plasmid Construction 
 
Sequences of all used primers (Sigma-Genosys) are given in Tables 10.3-10.9 (see Appendix). 
 
 
3.11.1 RORα4 Protein Overexpression in E. coli: pET28a-RORα4-6xHisN 
 
For cloning the coding sequence (cds) of human RORα4 into the empty vector pET28a, the 
pSG5-RORα4 vector (as a kind gift from C. Carlberg, Kuopio, Finland) was used. Two new 
restriction sites for NdeI and HindIII flanking the coding region were generated during 
amplification of the cds by PCR. The PCR product and the empty pET28a vector were 
digested with the restriction enzymes NdeI and HindIII and the insert was ligated into the 
vector subsequently. By performing this cloning strategy, hRORα4 was fused to a cleavable 
N-terminal hexahistidyl tag linked over a thrombin restriction site (LVPRGS), both provided 
in frame by the vector pET28a. The resultant construct was denoted as pET28a-RORα4-
6xHisN and the entire nucleotide sequence of the RORα4-6xHisN gene was verified by 
sequencing. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3: Plasmid map of pET28a-RORα4-6xHisN, containing a T7 polymerase promoter, the gene that 
encodes for the resistance to the antibiotic kanamycin and the coding sequence for hRORα4 flanked by a N-
terminal His-tag linked over a thrombin cleavage site. Primers for generating the new HindIII and NdeI 
restriction sites (underlined) are indicated. 
 
RORα4 mutants (T128A, T128D, T128E and others) were generated from wild-type by site 
directed mutagenesis. To introduce point mutations into the RORα4 coding sequence, a pair 
of two oligonucleotides was designed that were complementary to the respective opposite 
strand of the vector, but contained the desired mutations as mismatches. PCR cycle Materials and Methods 
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parameters were chosen as given in Table 3. 4. The template was digested with DpnI for 2-24 
h at 37°C and amplification product transformed into E. coli (sure). Successful mutagenesis 
was verified by sequencing. 
 
 
 
 
 
 
Table 3.4: PCR cycling parameters for site directed mutagenesis. 
 
3.11.2  hBmal1 Promoter: pGL3-Bmal1 
 
The human Bmal1 promoter sequence was amplified from genomic DNA obtained from 
Mono Mac 6 cells. Two oligonucleotides flanking the promoter sequence encompassing a 
MluI and a XhoI restriction site, respectively (as can be seen from Fig. 3.5), were designed 
and used for PCR. The amplification product and the pGL3 empty vector were digested with 
MluI and XhoI for 2 h at 37°C and restriction products were separated on an agarose gel. 
After DNA elution out of the gel, backbone and insert were ligated at 16°C for 4 h. By 
performing this cloning strategy, the Bmal1 promoter sequence was set in front of the 
luciferase coding sequence, activation of the Bmal1 promoter would result in luciferase 
protein expression. A schematical constitution of the resulting construct is given in Fig. 3.6 A. 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5: Sequence of hBaml1 promoter embedded in the pGL3 plasmid. Sequence is flanked by a MluI and a 
XhoI restriction site, by which it was cloned into the vector. Underlined sequences were used as primers for PCR 
(preceded by GATA). ROR response elements (ROREs) are marked in dark gray. Materials and Methods 
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3.11.3  hBmal1 Isoform A and B Protein Expression: pSG5-Bmal1-A, B 
 
The coding sequences of human Bmal1 isoform A and B were cloned from Mono Mac 6 
cDNA. PCR primers are shown in Fig. 3.6 B, two different forward primers were needed to 
generate the two isoforms A and B. Both forward primers embedded an EcoRI, the reverse 
primer a BglII restriction site, over which the amplified PCR product was ligated in the 
multiple cloning site of the pSG5 empty vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6 (A) Plasmid map of pGL3-hBmal1-prom, containing the human Bmal1 promoter in front of the 
luciferase coding sequence and a gene that encodes for the resistance to the antibiotic ampicillin. Primers for 
generating the MluI and XhoI restriction sites (underlined) are indicated. (B) Representative plasmid map of 
pSG5-hBmal1-A/B, that contains the coding sequence of hBmal1 protein isoform A or isoform B, respectively. 
Protein expression is regulated by a SV40 promoter. The gene encoding for the resistance to the antibiotic 
ampicillin and primers for generating the EcoRI and BglII restriction sites (underlined) are indicated.  
B 
A Materials and Methods 
40 
3.11.4  Determination of Anti-RORα Antibody Epitope: pEGFP-C2-HI-LBD-1-6 
 
For determination of anti-RORα antibody epitope, expression plasmids for six different 
RORα truncation mutants fused to EGFP were cloned. Each of them contained the coding 
sequence of the RORα ligand binding domain, a part of the hinge domain varying in length, 
and the EGFP coding sequence. Six different PCRs with pSG5-RORα4 as template were 
arranged. The six forward primers (as indicated in Fig. 3.7) annealed at six different positions 
within the hinge domain coding sequence, the reverse primer annealed at the end of the cds of 
the ligand binding domain. The varying length of resulting amplification products was 
controlled by agarose gel electrophoresis. After digestion of PCR products and the pEGFP-C2 
empty vector (Clontech) with HindIII and Acc65l, the hinge-LBD fragments 1-6 were set 
behind the EGFP cds. A plasmid map is given in Fig. 3.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7: Cloning of pEGFP-HI-LBD1-6. Coding sequence of hinge and LBD embedded in pSG5-RORα4, hinge 
domain is marked in light gray. Six forward (f1-f6) and one reverse (rev) primers were designed for PCR. The 
resulting truncation mutants differ in the length of their hinge domain. 
 
 
 Materials and Methods 
41 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8: Representative plasmid map of pEGFP-C2-HI-LBD-1-6. Expression of the EGFP-HI-LBD mutants 1-
6 is controlled by a CMV promoter. The gene that encodes for the resistance to the antibiotic kanamycin and 
primers for generating the HindIII and Acc65l restriction sites (underlined) are indicated. 
 
 
3.11.5  Ca/Dn-MEK1 Expression Plasmid: pcDNA3.1(+)-ca/dn-MEK1 
 
The coding sequence of MEK1 was cloned from cDNA of Mono Mac 6 cells in two 
fragments encompassing 481 and 701 bp, respectively. Primers for amplification of the 481 
bp-fragment contained a HindIII (for) and an EcoRI (rev) restriction site, primers for the 701 
bp fragment embedded an EcoRI (for) and a XhoI restriction site (see Fig. 3.9, restriction sites 
are underlined). After double-digestion of the purified PCR fragments and the empty 
pcDNA3.1(+) vector with the respective enzymes, fragments and backbone were ligated. The 
resulting construct was controlled by sequencing. 
In order to generate a constitutive active (ca) form of MEK1, two mutations were introduced 
into the MEK1 cds by site directed mutagenesis. MEK1 Ser-218 was replaced by glutamic 
acid and Ser-222 by aspartic acid subsequently. The dominant negative (dn) MEK1 was 
obtained by mutation of Lys-97 to methionine. Primers for generation of MEK1-S218E-
S222D (ca) and MEK1-K97A (dn) are described in Table 10.9 (Appendix). A representative 
plasmid map is given in Fig. 3.9. Functionality of the two constructs and MEK1 protein 
expression were tested by transfection of HeLa cells and immunoblotting with anti-MEK1 
antibody.  
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Fig. 3.9: Representative plasmid map of pcDNA3.1(+)-ca/dn-MEK1. Expression of ca/dn-MEK1 is controlled 
by a CMV promoter. The genes that encode for the resistances to the antibiotics ampicillin and neomycin and 
primers used for cloning are indicated.  
 
 
 
 
3.11.6  SUMO1 Expression Plasmid: pSG5-SUMO1  
 
The coding sequence of SUMO1 was cloned from Mono Mac 6 cDNA using the following 
primers (restriction sites underlined): 
 
SUMO1-SpeI-for:   GCCACCACTAGTATGTCTGACCAGGAGGCAAAACCTTC 
SUMO1-HindIII-rev: GCCACCAAGCTTAACTGTTGAATGACCCCCCGTTTG 
 
The resulting 327 base pairs amplification fragment was restricted with SpeI and HindIII and 
analyzed by agarose gel electrophoresis. After DNA elution out of the gel, the PCR product 
and pSG5 empty vector were double-digested with SpeI/HindIII and the SUMO1 coding 
sequence was inserted in the opened pSG5 empty vector. 
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4 RESULTS 
 
4.1  Overexpression and Purification of Human RORα4 in E. coli 
 
4.1.1 RORα4 Overexpression 
 
Overexpression of eukaryotic, especially human proteins in bacterial strains like Escherichia 
coli is a very effective method to obtain large amounts of pure protein. By transformation of a 
vector that contains the protein coding sequence into one of the common bacterial strains for 
overexpression, almost every human protein can be produced in full-length, or as truncation 
mutant for investigation on functional domains. Fusion of an additional N- or C-terminal 
polyhistidine tag to the target protein facilitates an easy purification, by the fusion of GFP 
(green fluorescent protein), the transfected recombinant protein can be visualized and 
observed inside intact cells. A variety of further useful tags had been developed that influence 
protein solubility, localization, the affinity to diverse reagents or protein recognition, showing 
that this kind of genetic engineering provides a lot of possibilities.  
In order to obtain pure and native RORα4 protein for biochemical investigations, a method for 
overexpression in E. coli and subsequent purification was established. For this purpose, 
pET28a-RORα4, a constructed plasmid containing the RORα4 coding sequence fused to a N-
terminal polyhistidine tag, was transformed into E. coli and the rate of RORα4 protein 
production during cell cultivation optimized. Different parameters concerning the 
overexpression host, culture and induction conditions were varied. As overexpression host, 
three kinds of E. coli strains were tested, BL21 (DE3), BL21 pLysS and Rosetta, however, the 
use of different strains did not influence the expression efficiency significantly. Finally, 
E. coli BL21(DE3) was chosen because of its rapid growth rate. As culture medium Luria 
Broth (LB) standard nutrient was used, and the impairment of culture conditions by addition 
of 3% ethanol or the use of M9 minimal salt medium plus casein hydrolysate diminished 
protein yield (Fig. 4.1 B). RORα4 expression yield was sensitive to the modification of 
induction conditions. Start of protein expression with 1 mM Isopropyl-β-D-
thiogalactopyranoside ( IPTG) at an optical density (measured at 660 nm, OD660) lying 
between 0.4 and 0.6, and 22°C as incubation temperature after the point of induction were 
found to be important parameters to enhance RORα4 protein expression (Fig. 4.1). Variation 
of IPTG concentration had no influence on expression efficiency. Cells were harvested and Results 
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lysed by sonication, supernatant and insoluble residues were separated by centrifugation and 
analyzed by SDS-PAGE. In all cases RORα4 protein appeared to be nearly exclusively 
expressed as inclusion bodies and therefore found in an insoluble form in the centrifugation 
pellet. 
Based on the yield optimizing studies, the following conditions were set as standard protocol 
for overexpression of RORα4:  E. coli BL21 (DE3) cells harboring the plasmid pET28a-
RORα4 were grown at 37°C with shaking overnight in 20 ml of LB medium containing 
kanamycin (50 µg/ml). A 6 ml aliquot of this culture was diluted into 500 ml of the same 
medium and grown at 37°C with shaking. When cells reached an OD660 of 0.4-0.6, addition 
of IPTG to a final concentration of 1 mM induced expression from the T7 promoter. After 
growth was continued for another 4 h at 22°C, cells were harvested by centrifugation at 
12,000 rpm in a Sorvall GSA rotor for 15 min at 4°C. The cell pellet was frozen and kept at 
-20°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.1: Optimizing RORα4 overexpression conditions. Cell aliquots were harvested immediately before and 
4  h after induction with IPTG. Bacteria were lysed with loading buffer and analyzed by SDS-PAGE with 
subsequent Coomassie brilliant blue staining of the gel. Equal cell amounts were loaded onto each lane. 
(A) Variation of optical density at induction point. Cells were grown at 37°C with shaking, optical density was 
determined with a Hitachi U-2000 spectrometer at 660 nm (OD660). IPTG was added to a final concentration of 
1 mM. The arrow points at the RORα4 migration height, RORα4 yield at induction of the optimal optical density 
is indicated. (B) Variation of culture medium and incubation temperature. The arrow points at RORα4 protein at 
optimized culture conditions. 
A 
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4.1.2  Separation of Inclusion Bodies and Refolding 
 
As mentioned above, RORα4 was expressed in an insoluble, denatured and therefore inactive 
form, as it is often observed when eukaryotic proteins get overexpressed in prokaryotes. The 
attribute of insolubility was used for purification, by washing the pellet with 1% Triton X-100 
about 70% protein purity could be achieved . Subsequently, the protein was solubilized in 6 M 
guanidine and refolded into the native structure.  
The cell pellet from 1.5 l E. coli culture (approx. 5-6 g wet weight) was thawed and lysed by 
suspending in 20 ml lysis buffer (25 mM Tris-HCl pH 8, 0.5 mM EDTA, 1 mg/ml lysozyme, 
5 µg/ml DNaseI and 10 µg/ml RNaseA) and sonication on ice for 20 min with 50% cycles 
using a Bandelin Sonoplus HD 200 sonicator. The homogenous suspension was centrifuged at 
4,000 rpm in a Heraeus Sepatech 8080E rotor for 10 min and the supernatant representing the 
soluble cell fraction was discarded. The insoluble cell fraction was washed three times with 
50 ml 1% Triton X-100 each. SDS-PAGE analysis was used to check the effectiveness of the 
purification procedure (Fig. 4.2).  
 
 
 
 
 
 
 
 
 
 
Fig. 4.2: SDS-PAGE analysis of RORα4 overexpression in E. coli. Lanes 1-6 stained with Coomassie brilliant 
blue: 1-2: total cell proteins from E. coli immediately before and 4 hours after induction with 1 mM IPTG, 
3:  soluble supernatant of lysed cells, 4-5: supernatant of inclusion bodies washed with 1% Triton X-100, 
6: insoluble inclusion body fraction. Lanes 7-8 immunoblot using anti-RORα antibody (Santa Cruz), followed by 
staining with NBT (330 µg/ml) and BCIP (170 µg/ml): total cell proteins from E. coli before and after induction 
with 1 mM IPTG, respectively. Equal cell amounts were loaded onto each lane. 
 
 
The RORα4 inclusion body pellet (about 70% purity) was dissolved in refolding buffer A (6 
M guanidine-HCl (Sigma), 20 mM NaH2PO4  pH 9.3, 0.1 M KCl, 6 mM DTT, 25 µM 
Zn(OAc)2) to a final concentration of approx. 25 µg/ml protein and heated at 100°C for 10 
min. Insoluble residues that might act as seed crystals were separated by another 
centrifugation at 4,000 rpm for 5 min. 4 ml of denatured RORα4 solution were renatured by 
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dialysis against a 100-fold volume of refolding buffer A with stepwise descending guanidine 
content (4 M, 2 M) for 3 h at 4°C each, followed by dialysis against a 100-fold volume of 
refolding buffer B (0.5 M L-arginine (Fluka), 20 mM NaH2PO4 pH 9.3, 0.1 M KCl, 6 mM 
DTT, 25 µM Zn(OAc)2) overnight. Dialysis was continued by using refolding buffer B with 
stepwise descending L-arginine content (0.3 M, 0.15 M, 0 M) for 3 h at 4°C each. To 
concentrate the protein solution 50% glycerol was added to the last dialysis step that was 
performed overnight at 4°C. Then the refolded protein was stored at -70°C. Protein 
concentration was determined by Bradford standard method, 200-300 µg/ml were achieved 
(overall yield 16-20 mg RORα4 per 1 liter E. coli culture). Fig. 4.3 shows an overview about 
the refolding procedure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.3: Schematical flowchart of RORα4 refolding procedure. Denatured RORα4 was dissolved in 6 M 
guanidine and refolded by dialysis against seven different buffers within three days.  
 
 
4.1.3  Nickel Affinity Chromatography 
 
For the purpose of applications requiring a further increased protein purity, a method utilizing 
Nickel affinity chromatography was developed. Therefore, the Nickel-ion affinity of the N-
terminal polyhistidine tag was utilized. For optimal protein recovery it was necessary to vary 
the buffer conditions during the refolding procedure. Addition of DTT was avoided since the 
presence of DTT impairs the resin by reduction of Ni
2+ ions. No Zn
2+ ions were added to the 
solutions because they might occupy the polyhistidine tag and prevent RORα4 from binding Results 
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to the resin. Nevertheless, Zn
2+ ions are essential for RORα4 activity and had to be added to 
the elution buffer. In the last refolding step the sample was dialyzed into purification buffer 
providing optimal column binding conditions (50 mM NaH2PO4 pH 8.0, 0.3 M NaCl, 50% 
glycerol). For batch purification, 2 ml of the refolded sample (approx. 500 µg RORα4) were 
applied onto 1.5 ml Ni-NTA agarose (Qiagen) equilibrated with equilibration buffer (50 mM 
NaH2PO4 pH 8.0, 0.3 M NaCl). After the protein-Ni-NTA mix was shaken very gently for 90 
min at 4°C, the slurry was poured into an empty column and the flowthrough was collected. 
Unbound proteins were washed off with a cascaded imidazole gradient (50 mM NaH2PO4 pH 
8.0, 0.3 M NaCl, with 20, 30, 40, 50 and 60 mM imidazole) and RORα4 finally eluted with 
elution buffer (50 mM NaH2PO4 pH 8.0, 0.3 M NaCl, 25 µM Zn(OAc)2, 250 mM imidazole). 
SDS-PAGE was used to analyze the purity of protein (Fig. 4.5). To determine RORα4 purity, 
gels were stained with Coomassie brilliant blue and gels were evaluated with Odyssey 
quantification software (Licor). RORα4 identity was controlled by Western Blotting on a 
PVDF membrane and incubation of the blot with anti-RORα antibody (Santa Cruz), followed 
by detection with nitro blue tetrazolium chloride (NBT, 330 µg/ml) and 5-bromo-4-chloro-3-
indolylphosphate (BCIP, 170 µg/ml). 
By performing a batch purification procedure, approx. 90% of the applied RORα4 protein 
bound to the resin. The protein was washed and eluted with an imidazole gradient, elution of 
RORα4 appeared between 50 and 100 mM imidazole, therefore the imidazole gradient in this  
interval is cascaded in a very fine way. While the color of the loaded sample was slightly
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4: SDS-PAGE analysis of RORα4 purification by nickel affinity chromatography. Proteins were stained 
with Coomassie brilliant blue. 1: refolded RORα4, 2: flow-through from Ni-NTA column; lane 3-9 elution 
fractions, elution with 250 mM imidazole. Equal proportions (20 µl solution) were loaded onto the various 
lanes. Results 
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brown, which was probable caused by insoluble non-protein E. coli residues, the eluted 
fractions were colorless and concentrations of 400 µg/ml were achieved. However, RORα4 
protein dimers, trimers and small fragments, bearing the N-terminal His-tag, possibly formed 
during sonication, could not be separated by Nickel affinity chromatography. 
 
 
4.1.4  DNA Binding Activity of Refolded RORα4  
 
The DNA binding activity of purified RORα4 was tested in an electrophoretic mobility shift 
assay (EMSA). The following complementary 5`-IRDye700 labeled oligonucleotides were 
annealed to generate double-stranded DNA fragments encompassing the ROR response 
element (RORE, underlined): 
 
RORE-sense 5` TCGAGTCGTATAACTAGGTCAAGCGCTGGAC 3`; 
RORE-antisense 5` GTCCAGCGCTTGACCTAGTTATACGACTCGA 3`. 
 
 
The EMSA standard 20 µl binding reaction mixture contained 1-2 µg of purified recombinant 
RORα4 protein, poly-dA-dT as competitor for unspecific DNA binding of proteins, and 
EGTA and Na3VO4 as inhibitors for remaining DNaseI residues from purification. Addition 
of bovine serum albumin (BSA) was needed to stabilize the labeled oligonucleotides. The 
reaction mixture was loaded on a 4% polyacrylamide gel and complexes were separated in 
0.5x Tris-borate-EDTA at 4°C. Gels were scanned with an Odyssey infrared imaging system 
(Licor). As can be seen from Fig. 4.5, refolded RORα4 was able to bind the ROR response 
element of the oligonucleotide, leading to a shifted band. The specificity of RORα4-DNA 
complexes was demonstrated by the addition of 2.2 µg anti-RORα-antibody to the binding 
reaction mixture which caused a complete loss of RORα4-DNA binding affinity. 
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Fig. 4.5: DNA binding activity of refolded RORα4 was analyzed by electrophoretic mobility shift assay 
(EMSA) with 5`-IRDye700 labeled, double-stranded oligonucleotides and recombinant RORα4 protein. 
Specificity of protein-DNA complexes was demonstrated by the addition of anti-RORα antibody. The RORα4-
DNA complex is indicated. 
 
 
4.1.5 Protein  Recovery 
 
At the point of cell harvest, RORα4 represents approx. 10% of the total bacterial proteins in 
transformed E. coli BL21(DE3). After sonication and washing of 5-6 g E. coli pellet wet 
weight (from 1 Liter culture), 18-22 mg denatured and inactive inclusion body protein could 
be recovered. Subsequent Ni-affinity chromatography facilitated an overall yield of 16-20 mg 
per 1 liter E. coli culture. Quantification was performed from Coomassie gels using Odyssey 
Application Software (Licor). 
 
 
 
 
 
 
 
 
 
Fig. 4.6: Purification table of recombinant RORα4 from 1 liter E. coli 
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4.1.6  Overexpression of Human RORα4 in HeLa 
 
For protein overexpression in eukaryotic HeLa cells, transient transfection was performed. 
Cell count as well as DNA amount were optimized (Fig. 4.7) as follows: 0.5-2.5×10
6 HeLa 
cells were seeded in plates with 9 cm diameter using Dulbecco´s Modified Eagle Medium (D-
MEM). Cells were transfected the following day with 20-70 µg expression vector pSG5-
RORα4 by the standard calcium phosphate method as described [217]. Cells were incubated 
with the precipitate for 16 h before medium was replaced. 24 h after transfection, cells were 
harvested and nuclear and cytosolic fractions were separated by incubation with 0.1% NP-40 
(in 10 mM Tris pH 7.4, 10 mM NaCl, 3 mM MgCl2, 1 mM EDTA, phenylmethanesulfonyl 
fluoride (PMSF), soybean trypsin inhibitor (STI), leupeptin) and centrifugation at 2700 rpm in 
a Heraeus Sorvall 3329 rotor for 10 min at 4°C. The supernatant represents the cytosolic 
fraction, the pellet nucleus and membranes. As shown in Fig. 4.7, 0.5×10
6 cells and 25 µg 
DNA were found as optimized conditions for RORα4 overexpression in HeLa cells.  
The resulting cell preparations were important tools to analyze antibody specificity or to 
perform localization experiments by Western Blotting described in the following chapters.  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.7: Optimizing RORα4 overexpression in HeLa. (A) Variation of cell count seeded one day before 
transfection of 50 µg pSG5-RORα4. (B) Variation of DNA amount used for preparation of precipitates applied 
onto 0.5x10
6 cells. N: nuclear, C: cytosolic fraction.  
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4.2  Generation of an Anti-RORα Antibody 
 
Antibodies are important tools for qualitative and quantitative detection of proteins in 
biochemical experiments. For a doubtless identification, these antibodies must feature high 
sensitivity and specificity, furthermore, the antibody itself should be characterized for a 
reasonable usage. In order to generate an antibody targeted against RORα, mice were 
immunized with recombinant human RORα4 protein. 
 
4.2.1  Preparation of Protein and Immunization 
 
Purified RORα4 inclusion bodies were used as basis for the recovery of the immunization 
serum. To avoid generation of an antibody targeted against the polyhistidine tag, this tag was 
cut off from RORα4 protein by taking advantage of the thrombin cleavage site. The inclusion 
body pellet from 1.5 l cell culture was dissolved by heating at 100°C for 7 min in cleavage 
buffer (200 mM Tris-HCl pH 8.4, 1.5 M NaCl, 25 mM CaCl2) containing 0.5% SDS. For the 
cleavage reaction, 10 units thrombin were added and the preparation was incubated at room 
temperature overnight. 
To obtain very pure RORα4 protein, the sample was loaded on a 10% polyacrylamide gel and 
bands corresponding to RORα4 were cut out of the gel. The protein was eluted out of the 
polyacrylamide gel by stirring the fragments in running buffer (0.2 M glycine, 25 mM Tris-
HCl, 3.5 mM SDS) overnight at 4°C. The solution was concentrated 10-fold by dialysis 
against 10% polyvinylpyrrolidone for 24 h at 4°C. Denatured RORα4 was renatured by 
dialysis against PBS containing 0.5 M L-arginine, 25 mM ZnSO4 and 26 nM cholesterol for 8 
h in a first step and against PBS overnight at 4°C in a second step. 
According to Brand et al. [220], about 50 µg RORα4 protein (determined by Bradford protein 
assay) in a final volume of 200 µl were injected i.p. into two female Balb/C mice. Eight 
immunizations were given with intervals of 15-21 days between the injections, a final i.p. 
boost was given three days before cell preparation. Each mouse was sacrificed under 
anesthesia and the spleen was dissected under sterile conditions. After fusing lymphocytes 
with NS-1 cells by adding PEG 4000, cells were separated into 96-well micro plates and 
supernatants of the growing clones were screened for antibody production by ELISA.  
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4.2.2  Control of Specificity 
 
Antibody specificity of a couple of clones was tested by Western Blotting. Probes from 
prokaryotic as well as eukaryotic cells were prepared, separated by SDS-PAGE and blotted on 
a PVDF membrane. After blocking the membrane surface with 5% milk (in TBS), the blot 
was incubated with clone cell culture supernatant, washed with TBS/Tween and incubated 
with anti-mouse antibody (alkaline phosphatase conjugated) subsequently. As can be seen 
from Fig. 4.8, the antibody producing clone 6E8 featured especially high sensitivity and 
specificity and was therefore chosen for further purification.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.8: Control of clone 6E8 antibody specificity by Western Blotting on a PVDF membrane. (A) General 
proteins versus proteins detected with clone 6E8. Left: Blot stained with Ponceau S, right: detection with clone 
6E8 followed by incubation with ECL. 1: untransformed E. coli, 2: E. coli transformed with pET28a-
RORα4,induced with 1 mM IPTG, 3: purified RORα4, 4: U266 nuclear extract + purified RORα4, 5: U266 
nuclear extract, 6: E. coli transformed with PKA-His. (B) Comparison of anti-ROR antibody purchased from 
Santa Cruz versus clone 6E8; Blots stained with NBT and BCIP. Left: detection with polyclonal anti-RORα 
antibody developed in goat (Santa Cruz); right: detection with monoclonal anti-RORα antibody clone 6E8 
developed in mouse. Lanes 1, 2: nuclear and cytosolic fraction of HeLa cells; 3, 4: nuclear and cytosolic 
fractions from HeLa cells transfected with pSG5-RORα4.  
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4.2.3  Purification of Anti-RORα Antibody Clone 6E8 
 
Purification of the IgG1 antibody from cell line 6E8 was performed using protein G 
Sepharose. Serum-free cell culture supernatant was adjusted to 20 mM NaH2PO4 pH 7.0 and 
applied to a column filled with protein G Sepharose resin equilibrated with binding buffer (20 
mM NaH2PO4 pH 7.0). After the resin was washed with binding buffer, the bound antibody 
was eluted with 100 mM glycine pH 2.5 and immediately neutralized by addition of 1/10 
volume of 1 M Tris-HCl pH 9. Antibody purity was controlled by SDS-PAGE and Coomassie 
brilliant blue staining. After dialysis against PBS, protein concentration was examined by 
Bradford protein assay using γ-globulin (from bovine plasma) as standard. Antibody solutions 
were stored at 4°C. 
 
 
 
 
 
 
 
 
 
Fig. 4.9: Purification of antibody from 200 ml cell supernatant. (A) Elution fractions were analyzed by SDS-
PAGE and Coomassie brilliant blue staining. Antibody was eluted from the column in fractions by addition of 
500 µl elution buffer each. (B) Concentration of elution fractions was determined by Bradford standard method. 
 
 
4.2.4  Determination of Epitope 
 
Since monoclonal antibodies bind to only one definite epitope, truncation mutants lacking 
different protein domains were cloned. The truncation mutants were transfected into HeLa 
cells, nucleic and cytosolic fractions blotted on a PVDF membrane and after blocking the 
surface with 5% milk, the membrane was incubated with antibody clone 6E8. 
In a first experiment two constructs were tested, pEGFP-A/B-DBD providing the A/B and the 
DNA binding domain, and pEGFP-HI-LBD that codes for the hinge and the ligand binding 
domain. Both truncated forms are fused to EGFP to facilitate the control of protein expression 
with help of an anti-EGFP antibody. As can be seen from Fig. 4.9, monoclonal antibody clone 
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6E8 detected the protein mutant composed of the hinge and ligand binding domain. The A/B-
DBD mutant was not detected, promising that the epitope was provided by RORα4 amino 
acids 83-468.  
 
 
 
Fig. 4.10: Determination of antibody epitope. (A) pEGFP-HI-LBD and pEGFP-A/B-DBD were transfected into 
HeLa cells, nuclear (N) and cytosolic (C) fractions were blotted on a PVDF membrane which was incubated 
with antibody clone 6E8 subsequently. (Occurrence of a putative cleavage fragment of 36.4 kDa  is discussed in 
chapter 4.4.2.) (B) Schematical constitution of truncation mutants.  
 
 
For further specification of the antibody epitope, the hinge domain was divided into six 
segments. As can be seen from Fig. 4.11, six constructs were cloned, HI-LBD 1-6 contained 
one to six of these hinge segments, fused to the ligand binding domain on the 3´-side and the 
EGFP coding sequence on the 5´-side.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.11: Schematical constitution of RORα4 protein and truncation mutants. HI-LBD 1-6 differ in the length 
of the hinge domain. Length of protein mutants and antibody epitope are indicated. 
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Truncated mutants were cloned by PCR using six forward primers that each bound to 
different locations on the hinge coding sequence and that were attached to a SacII restriction 
site. The reverse primer annealed at the end of the LBD and embedded a HindIII restriction 
site. The resulting fragments varying in length were ligated into the pEGFP vector over the 
SacII and HindIII restriction sites. pEGFP-HI-LBD-1 to -6 were transfected into HeLa cells 
and protein expression was demonstrated by incubation of Western Blot membrane with anti-
GFP antibody. As can be seen from Fig. 4.12, all mutants appeared at the predicted molecular 
weight. In contrast, incubation with clone 6E8 detected full-length EGFP-RORα4 and only 
one of the six constructs, HI-LBD-1, suggesting that the epitope lies between amino acids 83 
and 105. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.12: Western Blot of HeLa lysates transfected with EGFP-RORα4 or truncation mutants. HeLa cells 
were transfected in 9 cm Petri-dishes by calcium phosphate method, separation of nuclear (N) and cytosolic (C) 
fractions as described. Blots were incubated with (A) anti-ROR antibody or (B) anti-GFP antibody. Proteins 
were visualized by subsequent incubation with anti-mouse antibody (alkaline phosphatase conjugated) and 
NBT/BCIP. C: cellular, N: nuclear fraction. Predicted molecular weight of truncation mutants are indicated. 
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4.3  Phosphorylation of RORα4 
 
Phosphorylation is a key process for the regulation of nuclear receptor activity. Affected 
parameters are protein interaction with DNA or receptor coactivators/-repressors, subcellular 
localization, protein stability and degradation by the proteasome [47]. Against this 
background, a RORα phosphorylation as activity regulating event was taken into account. 
 
4.3.1  In-Gel Kinase Assay 
 
In order to screen for protein kinases that phosphorylate RORα4, in-gel kinase assays using 
purified recombinant RORα4 as substrate were performed. Isolated human 
polymorphonuclear leucocytes (PMNL) from healthy donors were incubated with different 
stimuli such as N-formyl-Met-Leu-Phe (fMLP), platelet activating factor (PAF), O-acetyl 11-
keto boswellic acid (AKBA), arachidonic acid, ionophore (Iono), phorbol 12-myristate 13-
acetate (PMA), sodium arsenite (SA) and sucrose for 1.5-3 min at 37°C. PMNL were 
immediately lysed by addition of 2x SDS-PAGE loading buffer and heated for 5 min at 
100°C. After sonication for 3 sec, aliquots of whole cell lysates were loaded on a 10% 
SDS/polyacrylamide gel that has been polymerized with purified and dissolved RORα4 
inclusion bodies (2.3 mg/ml) or myelin basic protein (0.5 mg/ml, MBP, positive control) or 
without addition of any protein (negative control). After electrophoresis, gels were incubated 
in 6 M guanidine. By washing out the guanidine, proteins were refolded within the gel matrix. 
Then gels were incubated in [γ-
32P]-ATP for 30 min at 30°C. Unbound [γ-
32P]-ATP was 
washed off, and the dried gel was incubated on imaging plates (IP) for 3 days. Phosphorylated 
proteins were visualized by a FLA-3000 IP Scanner (Fuji). As shown in Fig. 4.13 A, lysates 
from PMNL cells that have been stimulated with 40 µM arachidonic acid, 5 µM ionophore, 
100 nM PMA, 100 µM sodium arsenite or 570 mM sucrose gave phosphorylated bands at 
approximately 40 kDa in the RORα4 as well as in the MBP containing gels. In contrast, 
lysates of unstimulated cells or cells incubated with fMLP, PAF or AKBA lead to no 
phosphorylation signal.  
A database request at SwissProt (http://www.expasy.org/sprot/) registrated over 70 kinases 
with an approximate molecular weight of 40 kDa (+/- 6 kDa), including protein kinase A 
(PKA) and the mitogen activated protein kinases (MAPKs) p38 and ERK. In search for the Results 
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identity of the phosphorylating kinase, PMNL cells were pre-treated with different inhibitors 
of kinase activation and afterwards incubated with the stimuli described above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.13: In-gel kinase assays. (A) Cell extracts of human PMNL (10
6) in PBS containing 1 mg/ml glucose and 
1 mM CaCl2 were incubated for 1.5-3 min at 37°C in the absence or presence of diverse stimuli as indicated. 
Samples were separated over a 10% SDS-polyacrylamide gel which had been polymerized in the presence of 
either purified recombinant RORα4, myelin basic protein (MBP, positive control) or without addition of any 
protein (negative control). Gels were analyzed for protein phosphorylation by in-gel kinase assay as described 
[219]. fMLP: N-formyl-Met-Leu-Phe, 1 µM; PAF: platelet activating factor, 1 µM; AKBA: O-acetyl 11-keto 
boswellic acid, 100 µM; AA: arachidonic acid, 40 µM; Iono: Ca
2+-ionophore A23187, 5 µM; PMA: phorbol 12-
myristate 13-acetate, 100 nM; SA: sodium arsenite, 100 µM, Suc: sucrose, 570 mM. Positions of the standard 
proteins are indicated. (B) RORα4 phosphorylation is prevented by U0126. PMNL (10
6) were pre-incubated with 
3 µM U0126 for 10 min at 37°C and subsequently stimulated with ionophore (Iono), phorbol 12-myristate 13-
acetate (PMA) or arachidonic acid (AA) for 3 min. Aliquots were electrophoresed over a 10% 
SDS/polyacrylamide gel, which had been polymerized with 2.3 mg/ml purified recombinant RORα4. 
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10
6 PMNL cells were pre-treated with the ERK activation inhibitor U0126 (3 µM) [221,222] 
for 10 min at 37°C and subsequently stimulated with 5 µM ionophore, 100 nM PMA or 40 
µM arachidonic acid for 1.5-3 min, respectively. Cell lysates were prepared and subjected to 
in-gel kinase assay using RORα4 (2.3 mg/ml) as substrate. As shown in Fig. 4.13 B, pre-
incubation with 3 µM U0126 completely suppressed phosphorylation of RORα4 by the kinase 
appearing at 40 kDa, irrespective of the stimulus that was used. 
 
4.3.2  In Vitro Phosphorylation by ERK-2 
 
1-3 µg of purified and refolded RORα4 protein were incubated with commercially available 
ERK-2 (rat, recombinant) in an in vitro kinase assay. Clear bands corresponding to 
phosphorylated RORα4 were obtained after incubation with increasing concentrations of 
activated ERK. In absence of ERK no such bands appeared ruling out autophosphorylation or 
unspecific [γ-
32P]-ATP-binding (Fig. 4.14 A). 
The optimal consensus sequence for ERK1/2 is Pro-X-Ser/Thr-Pro (X can be any amino 
acid), whereas the last two amino acids Ser/Thr-Pro play the substantial role for recognition 
[185]. As shown in Fig. 4.14 B, the protein sequence of RORα4 contains six putative 
consensus motifs (PLTP at amino acids 126-129, TP at 153-154, SP at 173-174, TP at 193-
194, SP at 210-211 and SP at 332-333). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.14 In vitro phosphorylation of RORα4. (A) Recombinant RORα4 protein was purified and refolded as 
described. 3 µg RORα4 were incubated with activated ERK at 30°C for 30 min. Samples were loaded onto a 
10% SDS-polyacrylamide gel, phosphorylation of protein was detected by autoradiography. Myelin basic 
protein (MBP) was used as positive control. (B) Schematical representation of the RORα4 nuclear receptor, 
potential ERK phosphorylation sites are in bold. Thr-128 is located in the hinge region which connects the DNA 
binding (DBD) and the ligand binding domain (LBD). 
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In order to identify an ERK phosphorylation site, Thr-128, Thr-153, Ser-173, Thr-193, Ser-
210 and Ser-332 were mutated to alanine and the resulting mutants T128A, T153A, S173A, 
T193A, S210A and S332A were subjected to in vitro phosphorylation with ERK-2 as 
described. As shown in Fig. 4.15, only mutation of Thr-128 could anticipate phosphorylation, 
mutation of the other putative sites did not lead to a significant decrease in the 
phosphorylation signal. However, mutation of Thr-128 to alanine caused a complete loss of 
the phosphorylation signal and revealed Thr-128 as unique ERK-2 phosphorylation site. 
 
 
 
 
 
 
 
 
 
Fig. 4.15: RORα4 is phosphorylated by ERK-2 on Thr-128. pET28a-RORα4 mutants were obtained from WT 
by site directed mutagenesis. After production of insoluble proteins in E. coli BL21(DE3), inclusion bodies were 
isolated and refolded into the active form as described. Proteins were subjected to in vitro phosphorylation by 
ERK, gels were stained with Coomassie brilliant blue simultaneously to facilitate a comparison of protein 
amount. 
 
4.3.3  p38 and PKA  
 
Moreover, refolded RORα4 protein was incubated with recombinant protein kinase A (PKA, 
catalytic subunit from bovine heart) and p38 kinase (mouse, GST-fusion) for 30 min at 30°C, 
bovine MBP was used as positive control in both cases. In these in vitro kinase experiments 
PKA gave only moderately phosphorylated bands, and p38 failed to phosphorylate RORα4. 
 
 
Fig. 4.16:  In vitro  kinase  assay 
with PKA and p38. Purified and 
refolded RORα4 protein was 
incubated with each kinase at 30°C 
for 30 min. Probes were loaded on a 
10% SDS/ polyacrylamide gel. After 
drying, the gels were incubated on 
imaging plates for 24 h.  
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4.3.4  Receptor-RORE Complex Formation  
 
In order to compare the DNA binding properties of the RORα4-T128A mutant with RORα4 
wild-type, we subjected both proteins to an electrophoretic mobility shift assay (EMSA). 
RORα4 wild-type and -T128A were phosphorylated by incubation with ERK. For EMSA 
analysis, double-stranded, 5´-IRDye700 labeled oligonucleotides containing one copy of the 
ROR consensus motif AGGTCA were incubated with 1 µg of the pre-treated RORα4 wild-
type or RORα4-T128A, respectively. After 15 min on ice, samples were separated on a 4% 
non-denaturing polyacrylamide gel for 2 h, and shifted bands were visualized by scanning the 
gels with an Odyssey infrared imaging system (Licor). Interestingly, we observed that 
RORα4-T128A reveals a stronger binding affinity to the RORE compared to the wild-type 
protein (Fig. 4.17, first lane). For further comparison of the binding strength, we directly 
assessed the competition between RevErbα and RORα4-WT or -T128A for binding to the 
RORE. This was achieved by addition of increasing amounts of a nuclear extract containing 
RevErbα  to a fixed amount of RORα4  (1 µg). The addition of increasing amounts of 
RevErbα promoted formation of the RevErbα-DNA complex in a concentration-dependent 
manner. In the case of RORα4-T128A, a stronger formation of the receptor-DNA complex 
was detected compared to RORα4-WT, suggesting that RevErbα shows a reduced binding 
when competing with the T128A mutant (Fig. 4.17).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.17: Mutation of Thr-128 to alanine promotes receptor-RORE complex formation in an electrophoretic 
mobility shift assay. Left: a double-stranded 5´-labeled oligonucleotide embedding the ROR response element 
AGGTCA was used for testing the DNA binding affinity of RORα4 wild-type and -T128A. For competition 
experiment increasing amounts of RevErbα containing nuclear extracts were added to the DNA binding reaction 
mixture. Right: quantification of DNA complex formation was performed with Licor Odyssey software (Licor). 
The sum of ROR and RevErb shift intensities was set as 100%. Results 
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The influence of RORα4 phosphorylation status on DNA binding properties was tested by 
incubation of phosphorylated and unphosphorylated protein with the 5´-IRDye labeled RORE. 
Purified RORα4-WT and -T128A protein were incubated with ERK-2 or kinase buffer, 
respectively, for 30 min at 30°C. As shown in Fig. 4.18 A, phosphorylated and 
unphosphorylated wild-type protein displayed similar DNA binding properties. As expected, 
incubation with ERK did not affect T128A DNA binding affinity. 
Specificity of RORα4 and RevErbα shifts was verified by the addition of the respective 
antibody to the binding reaction mixture that caused a complete loss of detected shift bands 
(Fig. 4.18 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.18: (A) Influence of RORα4 phosphorylation on DNA binding affinity. Phosphorylated (30°C, 30 min, 
ERK-2) and unphosphorylated (30°C, 30 min, buffer) WT and T128A were incubated with 5´-IRDye labeled 
RORE as described. (B) Verification of shift specificity. Anti-RORα (6E8) and anti-RevErbα antibodies were 
added to the protein mixture prior to incubation with the RORE. 
 
 
4.3.5 Transcriptional  Activation 
 
The transcriptional activities of RORα4-WT and -T128A were compared in a reporter gene 
assay system. For this purpose two different promoter constructs were cloned: (i) the artificial 
REa23 promoter which is composed of three copies of the ROR response element AGGTCA, 
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was set in front of the TK-promoter and the luciferase coding sequence, and (ii) the 
physiological human Bmal1 promoter, embedding two ROR response elements AGGTCA 
and AGGTTA, which was cloned from Mono Mac 6 genomic DNA and set in front of the 
luciferase coding sequence. Both RORα4 wild-type and the T128A mutant were cotransfected 
in HeLa cells with each of these constructs, and relative luciferase activities were determined 
after 24 h (REa23) and 48 h (Bmal1), respectively. As can be seen from Fig. 4.19 A, the 
T128A mutant showed 1.6-2.4-fold higher inductions of the luciferase transcription than the 
wild-type receptor, for both the REa23 and the Bmal1-promoter. In addition, two 
phosphomimetic mutants RORα4-T128D and -T128E revealed transcriptional activities 
ranging between that of RORα4-WT and RORα4-T128A. Mutation of Thr-128 to Val or Ile 
also increased RORα4 transcriptional activity, whereas mutation of Thr-128 to Arg led to an 
attenuation. These observations suggest that RORα4 residue 128 represents a sensitive 
position within the functional RORα4 molecule, whose modification influences protein 
activity. Experiments performed with HEK293 cells led to similar activities for RORα4-WT 
and the mutants on both promoter constructs (Fig. 4.19 B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.19: Mutation of Thr-128 influences transcriptional activation. HeLa (40,000/well) or HEK293 
(100,000/well) cells distributed in 24-well-plates were cotransfected with 80 ng pSG-RORα4-WT, -T128A, 
-T128D, -T128E or empty expression plasmid and 400 ng pTKluc-REa23 or 800 ng pGL3-Bmal1 along with 
pCMV-SEAP using the calcium phosphate method. 16 h after transfection medium was changed and another 
24 h (REa23) or 48 h (Bmal1) later luciferase activities were determined. Luciferase values were normalized by 
secreted alkaline phosphatase activity values. For formation of x-fold inductions, relative luciferase activity of 
the empty vector plasmid was taken into account. Results are given as means of three independent 
experiments.* p<0.05, significant different from WT (Student´s t-test, one-sided). 
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4.3.6  Replacement by RevErbα 
 
It was previously shown that RORα  and RevErbα have opposing effects on a RORE. 
Whereas binding of RORα to its RORE activates gene transcription, RevErbα represents a 
constitutive repressor which functionally antagonizes RORα. Hence, the molecular ratio of 
RORα and RevErbα is the determinant for transcriptional activation [223]. Therefore, we 
assessed the possibility of RevErbα to antagonize the activities of RORα4 wild-type and 
RORα4-T128A in a reporter gene assay system. For this purpose varying ratios of RORα and 
RevErbα were cotransfected in HeLa cells and transcriptional activities were determined with 
REa23-luc as well as with the Bmal1-luc reporter construct. As can be seen from Fig. 4.20, 
substantially higher amounts of RevErbα were required to attenuate transcriptional activity 
induced by the RORα4-T128A mutant compared to the wild-type protein. Stability of the 
phosphomimetic mutants T128D and T128E against replacement by RevErbα was similar to 
that of the wild-type RORα4 (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.20: Mutation of Thr-128 to alanine prevents RevErbα to gain influence on the RORE. HeLa cells were 
cotransfected with 400 ng REa23 (A) or 800 ng Bmal1 (B) reporter construct along with varying ratios of the 
RORα4 (80-0 ng) and RevErbα (0-80 ng) expression plasmids. Luciferase values were normalized by secreted 
alkaline phosphatase activity values. Results are given as means of three independent experiments. 
* p<0.05,** p<0.01, significant different from WT (Student´s t-test, one-sided). Transfected cells were analyzed 
by Western Blotting to control expression of proteins (n: nuclear, c: cytosolic fraction), RORα4-WT and -T128A 
gave similar results. 
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4.3.7  PMA and U0126 
 
In order to investigate if direct activation or inhibition of cellular ERK effects RORα4 
transcriptional activity, transfected HeLa cells were incubated with 160 nM PMA, 20 µM 
U0126 or both compounds in combination. After 24 h relative luciferase activities were 
determined. Whereas incubation with PMA reduced RORα4 transcriptional activity by 75%, 
the ERK inhibitor U0126 was able to increase the activity up to 150%. Interestingly, a 
combination of both PMA and U0126 resulted in an unaltered induction when compared to 
incubation with the solvent DMSO. However, the T128A mutant was influenced by PMA and 
U0126 in a similar manner (Fig. 4.21 A). To further investigate whether the PMA/U0126 
effect is based on a second ERK phosphorylation site, five RORα4 double-mutants were 
cloned. Additive to the substitution of threonine in position 128, one of the five further 
potential phosphorylation sites was mutated, and the resulting double-mutants T128A-T153A, 
T128A-S173A, T128A-T193A, T128A-S210A and T128A-S332A were subjected to the 
PMA/U0126 incubation as described above. The activities of each double-mutant was 
decreased by PMA and increased by U0126, and all double-mutants acted similar to the 
T128A mutant. Western Blot experiments suggest that incubation of transfected HeLa cells 
with PMA reduces RORα4 protein expression (Fig. 4.21 B). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. 21: Effects of PMA and U0126 incubation on RORα4 transcriptional activity. (A) Expression plasmids 
for RORα4-WT and -T128A were cotransfected with pTKluc-REa23 in HeLa cells. 16 h after transfection 
medium was changed and cells were incubated with 20 µM U0126 30 min prior to the optional addition of 
160 nM PMA. Cells were harvested 24 h later and relative inductions were evaluated. Results are given as 
means of three independent experiments. (B) Transfected HeLa cells were blotted on a PVDF membrane and 
incubated with anti-RORα4 antibody clone 6E8. C: cytosolic, N: nuclear fraction. 
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4.3.8 Ca/Dn-MEK1 
 
In the signal transduction pathway, MEK (MAPK/ERK kinase) phosphorylates and thus 
activates ERK. Transfection of a constitutive active (ca) form of MEK leads to a permanent 
activation of cellular ERK [189,224], a dominant negative (dn) form inhibits the activation of 
cellular ERK [225,226]. In order to construct ca-MEK1, MEK1-S218D/S222D was cloned 
and inserted into the pcDNA3.1 empty expression vector, the dn-MEK was constructed by 
mutation of K97 to methionine. The resulting plasmids pcDNA3.1-MEK1-S218D/S222D and 
pcDNA3.1- MEK1-K97M were cotransfected with each the pSG5-RORα4 wild-type and the -
T128A mutant. Two different (ca/dn)-MEK1: RORα4 ratios were tested, 1:50 and 1:10, and 
the inductions were compared to cotransfection of the empty vector pcDNA3.1 as negative 
control. Neither the presence of constitutive active nor dominant negative MEK1 did alter 
RORα4 transcriptional activity significantly (Fig. 4.23). Expression of both MEK mutants 
was demonstrated by Western Blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.23: Cotransfection of constitutive active (ca) and dominant negative (dn) MEK1 with RORα4-WT and 
T128A in HeLa cells. (A) 72 ng pSG5-RORα4-WT or -T128A, were cotransfected with 8 ng pcDNA3.1-ca-
MEK1, pcDNA3.1-dn-MEK1 or pcDNA3.1 empty vector (1:10) on the REa23 promoter construct. Luciferase 
activities were determined 24 h after changing the medium and values were normalized with secreted alkaline 
phosphatase activity values. Relative inductions were obtained by comparison with the luciferase activities of the 
empty pcDNA3.1 vector. Results are given as means of three independent experiments. (B) Western Blot of 
nuclear fractions of transfected HeLa cells. Equal cell counts were loaded onto the various lanes. 
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4.3.9  Interaction with Bmal1 
 
Since phosphorylation of nuclear receptors can influence the interaction with other proteins 
[51,82], a direct interaction between RORα and Bmal1 protein was taken into account.  
Two expression vectors for the Bmal1 protein isoforms A and B, that only differ in their N-
terminal domains, were cloned and cotransfected in HeLa cells with RORα4-WT and -T128A 
mutant. As can be seen from Fig. 4.22, cotransfection of Bmal1A or B induced RORα4 
transcriptional activity 1.2 to 1.7 fold on the REa23 promoter construct, for both the WT and 
T128A mutant. In case of the human Bmal1 promoter, only Bmal1 isoform B induced RORα4 
transcriptional activity 1.5 fold. However, influence of the RORα4 phosphorylation status on 
the interaction with Bmal1A/B protein is not immediately apparent. PMA (160 nM)-
incubation of RORα4-WT or -T128A combined with Bmal1A/B reduced transcriptional 
activity in all cases, and had no influence on RORα activity inducing abilities of Bmal1 (data 
not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.22: Cotransfection of RORα4-WT or -T128A with Bmal1A/B on (A) pTKluc-REa23 and (B) pGL3-
Bmal1. HeLa cells (40,000/well) distributed in 24-well-plates were cotransfected with 40 ng pSG-RORα4-WT, 
 -T128A or empty expression plasmid and 40 ng pSG5-Bmal1A or B, together with 400 ng pTKluc-REa23 or 800 
ng pGL3-Bmal1 using the calcium phosphate method. 24 h (REa23) or 48 h (Bmal1) after the medium was 
changed, luciferase activities were determined. Luciferase values were normalized by secreted alkaline 
phosphatase activity values. Results are given as means of three independent experiments. For formation of x-
fold inductions, relative luciferase activity of the empty vector was taken into account.  
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4.3.10 Cellular  Distribution 
 
Cellular localization of RORα4 wild-type and the three mutants T128A, T128D and T128E 
was analyzed by Western Blot after separating the cytosol of transfected HeLa cells from the 
nuclei and membranes. As described previously [227], RORα4 is predominantly found in the 
nucleic fraction, only a small amount appears in the cytosol. Interestingly, both the 
unphosphorylatable as well as the phosphomimetic mutants revealed the same cellular 
distribution pattern (Fig. 4.24 A). Furthermore, Western Blot analysis showed that the wild-
type and all mutants are expressed at a similar level. The results of cellular distribution could 
be further confirmed by cloning of EGFP fusion proteins followed by the observation of 
transfected HeLa cells in a confocal laser scan microscope. These experiments confirmed the 
predominant localization of RORα-WT and all mutants in the nucleus. Even after 
cotransfection of increasing amounts of RevErbα, RORα4 was predominantly found in the 
nucleic fraction, neither the wild-type protein nor the T128A mutant showed an altered 
subcellular distribution. 
 
 
 
 
 
 
Fig. 4.24: Cellular localization of transfected RORα4-WT and -T128 mutants in HeLa cells. (A) 30 µg pSG5-
RORα4 and mutants were transfected into HeLa cells seeded in Petri-dishes with 9 cm diameter by calcium 
phosphate method. Medium was changed 16 h after transfection and another 24 h later cells were harvested. 
Cytosolic and nucleic/membrane fraction were separated and aliquots were subjected to SDS-PAGE and 
Western Blot. RORα was detected by antibody clone 6E8. C: cytosolic, N: nucleic/membrane fraction. (B) 
Transfected cells growing on glass cover slips were fixed with 4% paraformaldehyde in PBS after 24 h for 
10 min, permeabilized with 0.1 % Triton X-100 for 5 min and stained for 20 min with 1 mM TO-PRO-3 iodide in 
PBS with 1% BSA. Images were taken by confocal laser scan microscopy (CLSM). 
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Besides a predominantly nuclear and little cytosolic distribution, EGFP-tagged RORα4 was 
additionally detected at cellular membranes in HEK293 cells [227]. Therefore, we 
investigated whether phosphorylation status influences receptor membrane association. 
Neither mutation of Thr-128 nor incubation with 160 nM PMA did alter subcellular 
distribution of EGFP-RORα4 in HEK293 cells significantly. After cotransfection of 
increasing amounts of its opponent RevErbα, RORα4 was predominantly found in the nucleic 
fraction, neither the wild-type protein nor T128A changed the cellular compartment (data not 
shown).  
 
4.3.11  Degradation by the Proteasome 
 
It was postulated by Moraitis et al. [228] that RORα is ubiquitinylated and that subsequent 
degradation by the proteasome is needed to start transcriptional activation. This was 
demonstrated by the addition of the proteasome inhibitor MG-132 to a reporter gene assay 
system that led to decreased RORα activities. In order to investigate a connection between 
RORα4 phosphorylation status and degradation by the proteasome, the influence of MG-132 
on transcriptional activation of wild-type and T128A was determined on the REa23 promoter 
construct. Fig. 4.25 shows that the WT and T128A mutant are effected by MG-132 in a 
similar manner suggesting that the phosphorylation status has no influence on the degradation 
by proteasome. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.25: Influence of MG-132 on transcriptional activity of RORα4-WT and –T128A. 40 ng pSG5-RORα4-
WT or -T128A were transient transfected along with pTKluc-REa23 in HeLa cells. 16 h after transfection 
medium was changed and incubated with 0.1, 0.2, 1.0 mM MG-132 or DMSO as control. After 24 h cells were 
harvested and relative inductions were evaluated. Results are given as means of three independent experiments. 
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4.4  Further Posttranslational Modifications 
4.4.1 Sumoylation 
 
When transfected into HeLa cells and detected by immunoblotting, RORα4 protein appears as 
a group of three bands that differ in approx. 5-10 kDa molecular weight, a case that might 
suggest a posttranslational modification like a sumoylation. A potential sumoylation site is 
composed of four amino acids: ψ-K-X-D/E/G, whereas ψ represents a hydrophobic and X any 
amino acid, within this recognition site, SUMO is covalently linked over the lysine (K).  
As can be seen from Fig. 4.26, the RORα4 amino acid sequence contains four consensus 
motifs, potential lysine sumoylation sites are located at K89, K185, K302 and K386. Site 
directed mutagenesis was performed to replace the potential sumoylatable lysines by alanine. 
The resulting mutants were denoted as K89A, K185A, K302A and K386A. Disappearance of 
one of the three observed bands would give evidence for a destructed sumoylation site. 
However, after transfection into HeLa cells and analysis by immunoblotting, all four mutants 
appeared as the typical pattern consisting of three bands, as it was observed for the wild-type 
protein. Moreover, SUMO1 protein was cloned from Mono Mac 6 cDNA and ligated into the 
pSG5 expression vector. Cotransfection of this SUMO1 overexpressing construct in 
ascending concentrations led to no additively detected bands. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.26: Test on RORα4 sumoylation. (A) Amino acid sequence of RORα4. Potential sumoylation consensus 
motifs are in bold. (B) 30 µg pSG5-RORα4 and mutants were transfected into 0.5x10
6HeLa cells seeded in 9 cm 
Petri-dishes, cellular and nucleic fractions were separated and blot was analyzed with anti-ROR antibody 6E8 
(C: cytosolic, N: nucleic fraction). 
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4.4.2  Protein Cleavage  
 
pSG5-RORα4, pEGFP-RORα4 and pEGFP-HI-LBD1 were transiently transfected into HeLa 
cells seeded in 9 cm Petri-dishes; after 24 h nucleic fractions were prepared and blotted on a 
PVDF membrane.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.27: Cleavage of RORα4 protein in transfected HeLa cells. Left: 0.5x10
6 HeLa cells seeded in Petri- 
dishes were transfected with 30 µg expression plasmid encoding RORα4-WT (A), EGFP-RORα4 (B) and EGFP-
HI-LBD1 (C). Nucleic fractions were isolated and blotted on a PVDF membrane. After blocking the membrane 
with 5% milk in TBS, blots were incubated with anti-RORα antibody clone 6E8 (left panel) and subsequent with 
Santa Cruz antibody (right panel). Right: Schematical structures and molecular weights of overexpressed 
proteins. Proposed cleavage sites and resulting fragment weights are indicated. 
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As can be seen from Fig. 4.27 A, incubation of wild-type protein with monoclonal anti-ROR 
antibody clone 6E8 visualized two clear bands: one band at 55 kDa as expected for the intact 
protein and additively a fragment at 20 kDa probably caused by protein cleavage. Subsequent 
incubation with the polyclonal anti-RORα antibody purchased from Santa Cruz visualized a 
third clear band at 35 kDa, probably the second cleavage fragment. All three bands were not 
detected after transfection of the pSG5 empty vector into HeLa cells. Western Blot of 
transfected HeLa cells expressing the 82 kDa-sized EGFP-RORα4 (Fig. 4.27 B) showed 
additively to the expected band at 82 kDa a clear band at 47 kDa. Santa Cruz polyclonal anti-
ROR antibody revealed a second fragment at 35 kDa. Overexpression of EGFP-HI-LBD1 in 
HeLa revealed a similar pattern, the 72 kDa-sized protein showed an additive band at 37 kDa 
(Fig. 4.27 C). These three experiments clearly suggest a cleavage of RORα4 protein in 
transfected HeLa cells. Addition of the fragment molecular weight values always resulted in 
the molecular weight value of the protein in full-length, irrespective of which mutant was 
analyzed. Detailed theoretical considerations of the putative antibody epitopes and the 
respectively detected fragments indicated that the cleavage site is located within the hinge 
region. Further studies will be necessary to clearly identify the cleavage motif and to 
investigate the mechanism of RORα4 cleavage. So far, there is no evidence that 
phosphorylation on T128 by ERK influences RORα4 protein cleavage. Results 
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4.5 RevErbα 
 
4.5.1  Overexpression and Purification 
 
The coding sequence of RevErbα was cloned into the pET28a vector and the resulting N-
terminal His-tagged protein was overexpressed in BL21(DE3) in analogy to the protocol for 
RORα4 overexpression and purification. RevErbα inclusion bodies were washed with 1% 
Triton-X100, and purification procedure was analyzed by SDS-PAGE and Coomassie brilliant 
blue staining of the gel (see Fig. 4.28). The identity of RevErbα protein was verified by 
Western Blot and subsequent immunodetection with anti-RevErbα antibody. Per 1 l E. coli 
culture, approx. 2 mg RevErbα inclusion bodies of 50% purity could be recovered. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.28: Analysis of RevErbα overexpression and purification (1.5 l E. coli culture). Probes (20 µl each) 
were separated on a 10% SDS/polyacrylamide gel and stained with Coomassie brilliant blue. 
Lanes 1, 2: uninduced and with 1 mM IPTG induced BL21(DE3)-pET28a-RevErbα (equal cell amounts), 3: 
insoluble fraction of sonicated E. coli (dispersed in 15 ml), 4: soluble supernatant from inclusion body washing 
with 50 ml 1% Triton X-100, 5: purified inclusion body fraction (dispersed in 15 ml). The arrow indicates the 
migration height of RevErbα. 
 
 
4.5.2  Phosphorylation of RevErbα 
 
The possibility of RevErbα phosphorylation was investigated by performing an in-gel kinase 
assay. Freshly isolated human PMNL were incubated with different stimuli such as ionophore 
(Iono), arachidonic acid (AA), phorbol 12-myristate 13-acetate (PMA), sodium arsenite (SA), Results 
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di-buturyl-cAMP (db-cAMP), sucrose and N-formyl-Met-Leu-Phe (fMLP) for 1.5-3 min at 
37°C. PMNL were lysed by the addition of 2x SDS-PAGE loading buffer and aliquots of 
whole cell lysates were loaded on a 10% SDS/polyacrylamide gel that has been polymerized 
with purified RevErbα (approx. 2 mg/ml). After electrophoresis, proteins were refolded within 
the gel matrix and incubated in presence of [γ-
32P]-ATP for 30 min at 30°C. Gels were 
washed intensively to remove unbound [γ-
32P]-ATP, dried and incubated on an imaging plate 
for 3 days. As shown in Fig. 4.29, lysates from PMNL cells that have been stimulated with 
5 µM ionophore, 40 µM arachidonic acid, 0.1 µM PMA, 100 µM sodium arsenite or 1 µM N-
formyl-Met-Leu-Phe gave phosphorylated bands at approximately 40 kDa in the RevErbα 
containing gels. In contrast, lysates of unstimulated cells or cells incubated with db-cAMP or 
sucrose lead to no phosphorylation signal. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.29: RevErbα is phosphorylated in an in-gel kinase assay. Total cell extracts of human PMNL (10
6) in 
PBS containing 1 mg/ml glucose and 1 mM CaCl2 were incubated for 1.5-3 min at 37°C in absence or presence 
of ionophore (Iono), arachidonic acid (AA), or phorbol 12-myristate 13-acetate (PMA), sodium arsenite (SA), 
di-buturyl-cAMP (cAMP), sucrose or N-formyl-Met-Leu-Phe (fMLP) in indicated concentrations. Aliquots were 
electrophoresed on a 10% SDS/polyacrylamide gel, which had been polymerized with approx. 2 mg/ml purified 
recombinant RevErbα. In-gel kinase assay was performed as described above. Dried gel was incubated on an 
imaging plate for three days and phosphorylated protein was visualized by scanning with a FLA-3000 IP 
scanner (Fuji). 
 
 
According to the experiments performed with RORα4, the approximate kinase size and the 
activating stimuli, PMNL cells were pre-treated with the ERK activation inhibitor U0126 
(3 µM) for 10 min at 37°C and subsequently stimulated with fMLP, SA, ionophore or PMA. 
As it was observed for RORα4, pre-incubation with U0126 diminished phosphorylation of 
RevErbα by the kinase appearing at 40 kDa, irrespective of the used stimulus (Fig. 4.30). 
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Fig. 4.30: RevErbα phosphorylation is prevented by U0126. Human PMNL were pre-incubated with 3 µM 
U0126 for 10 min at 37°C and subsequently stimulated with N-formyl-Met-Leu-Phe (fMLP), sodium arsenite 
(SA), ionophore (Iono) or phorbol 12-myristate 13-acetate (PMA). Aliquots were electrophoresed on a 10% 
SDS/polyacrylamide gel, which had been polymerized with 2 mg/ml purified recombinant RevErbα. Gels were 
analyzed for RevErbα phosphorylation by in-gel kinase assay. 
 
 
Purified RevErbα inclusion bodies were refolded exactly as it was described for RORα4 (see 
chapter 4.1.2). Since the inclusion body recovery was very low and the conditions for RORα4 
refolding were suboptimal for RevErbα, cultivation of 1.5 l transformed E. coli culture 
resulted in 170 µg of native RevErbα protein. Most protein loss occurred through 
precipitation during dialysis against the buffers with descending L-arginine content. 
Precipitates were removed by centrifugation and the remaining RevErbα solution 
concentration exceeded hardly 85 µg/ml. Nevertheless, 1 µg of refolded RevErbα was 
subjected to in vitro phosphorylation with ERK-2. As shown in Fig. 4.31 A, ERK was able to 
phosphorylate purified RevErbα protein, RORα4 was used as positive control. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.31: In vitro phosphorylation of RevErbα. (A) 1 µg refolded RevErbα protein (or RORα4 as positive 
control) was incubated with active ERK-2 in presence of [γ-
32P]-ATP at 30°C for 30 min. Probes were separated 
by SDS-PAGE and dried gel was incubated on an imaging plate for 48 hours. Phosphorylated proteins were 
visualized with a FLA-3000 scanner (Fuji). (B) Amino acid sequence of RevErbα protein, putative ERK 
recognition motifs are indicated. 
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The RevErbα amino acid sequence reveals 18 putative ERK recognition motifs (Fig. 4.31 B), 
but the actual phosphorylation sites still remain to be determined. 
In order to test whether activation of cellular ERK influences RevErbα repressing activity, the 
two nuclear receptors RORα4 and RevErbα, both in vitro phosphorylatable with extracellular-
signal regulated kinase, were cotransfected along with the REa23 promoter construct and 
incubated with 160 nM PMA or the equivalent volume of the solvent DMSO in D-MEM. 
However, RevErbα repressing activity was not affected by incubation with PMA. In a second 
experiment, stripped FCS was used. Treatment of FCS with charcoal extracts small lipophilic 
molecules, which could act as ligands for the nuclear receptors RORα and RevErbα. As 
shown in Fig. 4.32, usage of a medium supplemented with stripped FCS abrogated the 
increased activity of the T128A mutant completely, WT and mutant showed very similar 
activities in presence or absence of RevErbα. However, incubation with the protein kinase C 
activator PMA diminished entire transactivation, but again had no effect on RevErbα 
repressing activity. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.32: Influence of PMA incubation on transcriptional activity of the two nuclear receptors RORα4 and 
RevErbα on the REa23 promoter construct. 40 ng pSG5-RORα4-WT or -T128A were cotransfected with 40 ng 
pSG5- RevErbα or pSG5 empty plasmid in HeLa cells. After 16 h, medium with stripped FCS and 160 nM PMA 
(or DMSO) were added. Luciferase activity was determined after 24 h of incubation.  
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5 DISCUSSION 
 
RORα is a key regulator of a variety of physiological events with putative clinical relevance. 
Since it is involved in lipid and bone metabolism, where it shows protective effects against 
atherosclerosis and osteoporosis, and additionally negatively regulates inflammation, RORα is 
of increasing pharmaceutical interest (summarized in [88]). Little is known about RORα 
protein regulation or activity modulation by binding of endo- or exogenous ligands. On the 
basis of a reproducible protein production method and the development of an anti-RORα 
antibody, studies on RORα signaling pathways were performed. 
 
Overexpression and purification of RORα4 
In order to produce recombinant RORα4 protein in E. coli, the cDNA of human RORα4 was 
cloned into pET28a, a bacterial expression vector. The pET28a vector system was chosen for 
RORα4 expression because it is one of the most powerful tools yet developed for the 
overexpression of recombinant proteins in E. coli. The system is based on the very strong T7 
promoter, that, when transformed in a suitable E. coli overexpression strain, provides the 
possibility to active induction of recombinant protein expression by the addition of isopropyl-
β-D-thiogalactopyranoside (IPTG) to the culture. Moreover, the pET28a vector facilitated the 
generation of RORα4 protein fused to a N-terminal polyhistidine tag, which is linked via a 
thrombin cleavage site and can be removed if required. The polyhistidine tag was localized on 
the N-terminal site, since fusion to the C-terminal LBD could result in a sterical hindrance of 
ligand-receptor interaction. E. coli BL21(DE3) were transformed with the emerged vector 
pET28a-RORα4-6xHisN. However, by the use of the T7 expression system, production of 
target proteins proceeds very rapidly so that the expressed proteins are often misfolded and 
aggregate as insoluble inclusion bodies [229]. Inclusion bodies are composed of densely 
packed denatured protein molecules in form of insoluble particles. They consist mostly in 
only one type of polypeptide, which helps to isolate and purify the protein aggregates to 
homogeneity. However, to obtain native and bioactive protein, inclusion bodies have to be 
solubilized and refolded carefully. In the case of RORα4, a variety of experimental conditions 
were tested to obtain greater solubility, including the use of lower IPTG concentrations, 
induction at different cell densities (OD660 0.4-1.2), growth at different temperatures, variation 
of growth media (incl. addition of glucose or ethanol) and the use of diverse E. coli strains 
(Rosetta, BL21(DE3)pLysS), but none of the experimental conditions led to a greater yield of 
soluble hRORα4. Hence, the methodology focused on conditions to optimize the amount of Discussion 
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insoluble RORα4 inclusion bodies. Finally, 18-22 mg RORα4 inclusion bodies of ~70% 
purity were obtained per 1 l of cell culture. After isolation and purification of insoluble 
inclusion bodies, 6 M guanidine as a strong denaturant was used to solubilize the protein at 
the beginning of the refolding process. Refolding RORα4 into the native form included three 
phases: i) gradual removal of the denaturant guanidine and simultaneous addition of the 
adjuvant L-arginine, ii) gradual removal of L-arginine and iii) protein enrichment by dialysis 
against 50% glycerol. L-arginine is used to enhance the refolding process and to suppress 
aggregation of folding intermediates, but the mechanism is still intensively discussed. It was 
supposed that interactions between the guanidinium group of L-arginine and tryptophan side 
chains of the target protein may be responsible for suppression of protein aggregation (Fig. 
5.1) [230,231]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.1: Protein refolding. Denatured protein is transferred into its native form during gradual removal of 
denaturant. L-arginine is used as adjuvant suppressing aggregation of folding intermediates. 
 
 
Gradual removal of guanidine and L-arginine had to be performed very carefully to prevent 
reaggregation of solubilized protein. Most critical parameters were time, pH, buffer 
substances, and protein concentration. The pH had to be between 8 and 9, lower pH values 
lead to precipitation of recombinant RORα4. Addition of Zn
2+ ions was necessary for 
conformational development of the two zinc finger motifs in the DNA binding domain of the Discussion 
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protein. However, precipitation of Zn(OH)2 had to be avoided by keeping the pH below 9.3. 
The initial protein concentration was adjusted to maximal 20-25 µg/ml, like it was described 
by others to be a critical parameter to achieve the maximum refolding efficiency [232]. 
Various combinations of solubilizing agents (MgSO4, Chaps, L-glutamine/L-arginine) 
[233,234], refolding buffers (Tris-HCl, HEPES, addition of cholesterol) and methods of 
refolding (dialysis or slow dilution) were tested to improve the refolding efficiency. However, 
the described conditions were found to be optimal.  
The complete process lasted over three days, and after the last step of protein enrichment, the 
concentration of soluble protein achieved 200-300 µg/ml. At this concentration and solved in 
50% glycerol, refolded RORα4 could be stored at –70°C. The RORα4 DNA binding activity 
was tested by performing an EMSA, where RORα4 binding to a double-stranded, monomeric 
ROR response element was checked. The EMSA results suggest that the refolded protein is 
functional and that the N-terminal polyhistidine tag does not prevent correct folding or 
interferes with DNA binding activity. In order to check specificity of the RORα4-DNA 
complex, anti-RORα antibody was added to the binding reaction mixture which caused a 
complete loss of RORα4-DNA binding. 
To further increase protein purity, the refolded his-tagged RORα4 protein was loaded onto a 
nickel affinity column. For optimal protein recovery it was necessary to vary the buffer 
conditions: involvement of DTT destructed the resin by reduction of Ni
2+ ions, thus, addition 
of DTT should be avoided. The pH had to be adjusted to the binding optimum pH 8; 
moreover, addition of Zn
2+ ions was omitted, because Zn
2+ may occupy the His tag so it is not 
accessible for the Ni-resin. Nevertheless, Zn
2+ ions are essential for RORα4 activity and had 
to be added to the elution buffers at the latest. By performing a batch purification procedure, 
approx. 90% of the applied RORα4 protein bound to the resin. The protein was washed and 
eluted with an imidazole gradient, elution of RORα4 appeared between 50 and 100 mM 
imidazole, therefore, the imidazole gradient for column wash is cascaded in a very fine way 
within this interval. While the loaded sample was colored slightly brown, which was probably 
caused by insoluble non-protein E. coli residues, the eluted fractions were colorless and 
concentrations from 400 µg/ml could be achieved. However, RORα4 protein dimers, trimers 
and small fragments, bearing the N-terminal His-tag, possibly formed during sonication, 
could not be separated by Nickel affinity chromatography. 
 
In summary, a method for the overexpression of human full-length RORα4 in Escherichia 
coli was developed. Production of mg amounts of native RORα4 protein can be performed Discussion 
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easily within 4 days. Although the RORα4 protein was insoluble when expressed in E. coli, it 
could be refolded into an active conformation. Against former skepticism, refolding of 
insoluble proteins aggregates obtained from overexpression in prokaryotes became a common 
and accepted method for obtaining large amounts of native recombinant proteins in the past 
years [235]. Protocols for refolding procedures of a variety of proteins can be found at 
databases in the internet (http://refold.med.monash.edu.au/). Some general guidelines for 
developing a refolding procedure are apparent, but a specific protocol must be empirically 
determined for each protein. However, the functionality of refolded proteins has to be verified 
and the method is not appropriate for every protein. However, since the refolded RORα4 
recombinant protein showed the expected functionality, demonstrating that it was folded 
properly, it can be used as starting material for further investigative studies on the nuclear 
receptor RORα. 
 
Anti-RORα antibody 
Production of a new monoclonal anti-RORα antibody was achieved by injecting recombinant 
hRORα4 into Balb/c mice. To prevent the possibility of raising an antibody targeted against 
the polyhistidine epitope, the fused His-tag was cleaved before injection. Because injection of 
prokaryotic residues in mice causes an intense immune response, leading to a variety of 
antibodies targeted against E. coli proteins, high RORα4 purity was needed for immunization. 
This purity was obtained by separation of probe proteins by electrophoresis and subsequent 
excision of the RORα4 band out of the polyacrylamide gel. 
Eight injections with hRORα4 in PBS were sufficient for immunization, and after fusion of 
mouse lymphocytes with NS-1 cells, the hybridoma cell line 6E8 was identified as anti-RORα 
antibody donor. The quality of anti-RORα antibody was tested by immunoblotting using 
lysates of untreated HeLa cells and HeLa cells transfected with pSG5-RORα4. Antibody 
clone 6E8 showed high specificity and sensitivity and could be used for detecting of both 
denatured and native RORα4 protein. The antibody epitope was identified by immunoblot 
using various protein truncation mutants, and amino acids 83-105 of human RORα4 emerged 
as necessary for antibody recognition. These amino acids lie within the N-terminus of the 
conserved hinge domain, more precisely in the carboxy-terminal extension (CTE). The two 
arising advantages of this epitope location are: (i) all four RORα isoforms should be 
detectable with clone 6E8 and (ii) since the CTE was absolute necessary for monomeric DNA 
binding [93], binding of clone 6E8 to RORα4 protein diminishes its DNA binding affinity Discussion 
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significantly. Therefore, the anti-RORα antibody was optimal for demonstration of RORα 
shift specificity in the electrophoretic mobility shift assay (EMSA). 
 
RORα phosphorylation 
As mentioned above, activity of steroid as well as non-steroid nuclear receptor is regulated by 
phosphorylation. Phosphorylation of a nuclear receptor has multiple effects, DNA binding 
affinity is influenced, ligand-binding, recruitment of cofactors or protein stability. Besides the 
binding of a ligand, phosphorylation of nuclear receptors is a very important way to take 
influence on transcriptional activation (summarized in Table 1.7). 
Although cholesterol was found within the ligand binding pocket of RORα, it is not yet clear 
whether cholesterol is the natural ligand for RORα that functions as on-switch. Cholesterol-
deficient cells showed a decreased RORα activity which could be retrieved after cholesterol 
addition [120,121]. However, cholesterol is an essential component of cell membranes, and 
cell suffering after depletion of cholesterol is not remarkable. Molecular modeling suggest 
that RORα acts ligand-independent, because the primary amino acid sequence leads to a 
three-dimensional conformation similar to that of ligand-bound receptor [107]. Altogether, no 
activating or repressing agent has been doubtlessly identified so far.  
On this background, a posttranslational modification such as phosphorylation as activity 
regulating event was taken into account. In order to find a kinase that phosphorylates RORα, 
in-gel kinase experiments were performed. RORα4 was polymerized into a gel matrix, 
refolded within this matrix and subjected to in-gel phosphorylation with kinases provided 
from cell lysates that were separated over the gel. These cell lysates were prepared from 
freshly isolated PMNL cells which were stimulated with various substances to respectively 
activate different kinase groups. After separation of PMNL cell lysates within the RORα4 
containing gel matrix and incubation of the gel in a [γ-
32P]-ATP buffer, a RORα4 
phosphorylating kinase with an apparent molecular weight of approx. 40 kDa was detected. 
This kinase was activated by arachidonic acid, ionophore, PMA, sucrose or sodium arsenite 
incubation, these substances can all be considered as cell stressors. The ERK activation 
inhibitor U0126 suppressed this phosphorylation. PKA and p38 failed to phosphorylate 
RORα4 in vitro. Finally, ERK was found to phosphorylate RORα4 in vitro on Thr-128, which 
is part of an optimal ERK consensus sequence PLTP. Further in vitro experiments 
demonstrated that mutation of Thr-128 to alanine completely prevents phosphorylation of the 
RORα4 protein by ERK. Although five additional putative ERK recognition sites can be 
found in the RORα4 amino acid sequence, phosphorylation by ERK could only be Discussion 
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demonstrated for Thr-128. Thr-128 is located in the hinge region, which represents the 
connecting link between the DNA binding domain and the ligand binding domain, these three 
segments constitute the conserved part of all four RORα1-RORα4 isoforms, which only 
differ in their N-terminal A/B domain. Within the nuclear receptor subfamily, the hinge 
region shows little homology. Besides orientating the DBD and the LBD in a three 
dimensional conformation to each other, the hinge domain provides the carboxy-terminal 
extension (CTE) that recognizes the A/T-rich sequence in front of the response element 
AGGTCA. The proper conformation of both the protein and the DNA within the complex 
facilitates the interaction of the nuclear receptors with other components of the transcription 
machinery [14]. Thus, the hinge domain takes influence on DNA binding properties, 
facilitates a proper conformation by arranging the other receptor domains, and is responsible 
for the recruitment of cofactors that are necessary for interaction with the transcription 
machinery.  
Thr-128 was replaced by alanine and the resulting mutant T128A was not accessible for 
RORα4 phosphorylation by ERK in vitro. Experiments demonstrated that the RORα4-T128A 
mutant exhibits a stronger DNA binding affinity than the wild-type protein. This was shown 
by an electrophoretic mobility shift assay and confirmed when the transcriptional activity was 
tested in a reporter gene system, where the T128A mutant showed an increased activity when 
compared to RORα4-WT. Presumably, the increased DNA binding affinity of the T128A 
mutant led to an enhanced transcriptional activity. Moreover, in competition experiments with 
RevErbα, the T128A mutant was more resistant to replacement by RevErbα at the RORE. 
However, there is little evidence that the lack of phosphorylation contributes to the stronger 
DNA affinity of the T128A mutant. The phosphomimetic mutants, T128D and T128E, 
displayed an activity that was in the range between that of WT and the T128A mutant, and it 
remains unclear whether the mutants perform their task as phosphomimetics properly. 
Physical exchange of amino acid 128 to valine or isoleucine also increased RORα4 
transcriptional activity. In contrast, mutation to arginine, bearing a positive charge, attenuated 
the activity. These results suggest that residue 128 is a sensitive site whose constitution takes 
influence on RORα4 DNA binding affinity. Residue 128 is located not far from the carboxy-
terminal extension (CTE), which comprises amino acids 83-111 and was shown to bind to the 
A/T-rich sequence preceding the ROREs. In fact, binding of the CTE is absolute necessary for 
binding of RORα to its response element, because truncation of this domain led to a complete 
loss of DNA binding abilities in vitro [87,93]. Unfortunately, it was not possible to influence Discussion 
82 
the DNA binding affinity by phosphorylation of RORα4 protein in vitro. In an electrophoretic 
mobility shift assay, phosphorylation by ERK-2 did not affect RORα4 binding affinity. 
In order to demonstrate an effect of the actual Thr-128 phosphorylation status on 
transcriptional activity in vivo, cellular kinases were stimulated by incubation of HeLa cells 
with PMA. PMA incubation of transfected HeLa cells decreased RORα4 activity, and the 
specific inhibitor of ERK activation U0126 could neutralize this effect. However, the activity 
of the T128A mutant was modulated in a similar manner, and the additional mutation of one 
of the other five putative phosphorylation sites gave the same results. This clearly 
demonstrates that the PMA/U0126 effects are not evoked by stimulation and inhibition of 
RORα4 phosphorylation by ERK. A direct influence of ERK activation/inhibition on RORα4 
transcriptional activity could not be shown. Western Blots of transfected cells demonstrated 
that incubation with PMA impaired RORα4 expression which could explain the diminished 
RORα4 transcriptional activation of the TK-promoter in front of the luciferase coding 
sequence. 
MEK1 is the upstream kinase which phosphorylates and thus activates ERK. To particularly 
activate cellular ERK in transfected HeLa cells, a constitutive active form of MEK1 was 
cloned and cotransfected. A slight activation of ERK in the cell nuclei was demonstrated by 
immunoblotting of transfected HeLa cells using an anti-phospho-ERK antibody. However, 
RORα4 activity was not influenced by cotransfection of ca-MEK1, even a dominant negative 
form which should suppress ERK activation, did not seem to influence RORα4 activity. 
Within the core-clock of mammals, oscillating expression of Bmal1 protein is responsible for 
impulse generation. RORα seems to constitutively activate Bmal1 expression. RevErbα 
suppresses RORα transcriptional activation and thus takes the counterpart. Importantly, 
RevErbα represses its own expression which results in an oscillating appearance of RevErbα 
nuclear receptor. This oscillating appearance leads to an oscillating RORα antagonism and 
finally to an oscillating Bmal1 expression. Altogether, the actual pacemaker in the core-clock 
of mammals is the feedback loop of RevErbα repressing its own transcription. Within the 
core-clock, there are various further feedback loops. Therefore, another feedback loop 
between RORα and Bmal1 protein was considered. In fact, cotransfection of Bmal1 enhanced 
RORα4 activity on the Bmal1 promoter in an isoform-specific manner. Whereas isoform A 
seemed to have no influence, isoform B induced RORα4 activity up to 150%. However, a 
correlation between this activity induction and RORα4 phosphorylation status is not 
immediately apparent, because the T128A mutant was inducible in a similar manner. Discussion 
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In HeLa cells, RORα4 is predominantly located in the cell nucleus [227]. RORα4-WT, 
-T128A and -T128E were fused to EGFP and transfected HeLa cells were observed in a 
confocal laser scan microscope. However, mutation of Thr-128 did not influence the cellular 
distribution pattern. Besides a clear nuclear localization, RORα4 was additionally found as 
protein clusters at cellular membranes of HEK293 cells, indicating that the nuclear receptor 
might have further tasks outside the cell nucleus. But again, neither mutation of Thr-128 nor 
incubation with PMA affected the appearance of the membrane clusters. 
Besides directly regulating nuclear receptor activity, phosphorylation was demonstrated to 
influence protein stability and degradation by the proteasome [46,67]. Experiments on 
RORα4 long-term stability over 6 days and experiments on RORα4 degradation by the 
proteasome, showed no correlation to the phosphorylation status. Transfected RORα4 wild-
type and the T128A mutant exhibited the same stability over 6 days in HeLa cells. 
 
Altogether, these results indicate that RORα4 is phosphorylated on Thr-128 by ERK in vitro, 
but within our assay systems we could not demonstrate that this phosphorylation has an effect 
on transcriptional activation, protein stability or cellular distribution in HeLa cells. Further 
luciferase experiments with HEK293 and MCF-7 cells suggest similar results. Nevertheless, 
mutation of Thr-128 to Ala changes RORα4 DNA binding affinity and influences the 
transcriptional activity, probably because of its location nearby the CTE.  
There is a high probability for a cellular relevance of an optimal ERK consensus motif that is 
conserved in all four RORα isoforms. Further studies should be performed to prove an 
influence on binding affinity to different types of ROR response elements. Alternatively,   
phosphorylation on the hinge region could be necessary for direct interaction with an 
unknown protein modulating RORα activity, and the expression level of this co-regulator 
protein is too low within the artificial conditions of a reporter gene assay. Moreover, 
phosphorylation was shown to prepare proteins for further modifications, for example for a 
sumoylation or a second phosphorylation by another kinase. A recent study reported that ERK 
phosphorylates mCry1 (Ser-247) and mCry2 (Ser-265), two transcription factors necessary for 
the maintenance of the core-clock rhythm [175]. Phosphorylation on these residues by ERK 
reduces mCry repressing activity. Interestingly, physiological relevance of a second ERK 
phosphorylation site in mCry2, Ser-557, was initially unclear. Lately it was demonstrated that 
phosphorylation on Ser-557 prepares mCry-2 protein for an additional phosphorylation by 
glycogen synthase kinase-3 beta (GSK-3β), which is needed for an efficient degradation of 
protein by the proteasome [176]. Discussion 
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RevErbα phosphorylation 
Because of the obvious sequence homology between RORα and its opponent RevErbα, it was 
possible to apply the RORα4 overexpression and purification protocol for RevErbα protein 
production. Although the conditions might be further optimized, the protein was produced in 
an acceptable quality and quantity by inclusion body separation and protein refolding. 
Purified RevErbα inclusion bodies were used to prepare the gels for in-gel kinase assays. In 
analogy to the experiments performed with RORα, it could be demonstrated that RevErbα is 
also a target for ERK-2 phosphorylation in vitro. Analysis of the RevErbα amino acid 
sequence reveals 18 putative ERK recognition sites. Initial experiments on physiological 
relevance of this phosphorylation, by incubation of an RORα4-RevErbα interplay on the 
REa23 promoter with PMA, gave no hints so far.  
 
Herein, it was shown that RORα as transcriptional activator and RevErbα as transcriptional 
repressor can be both phosphorylated by ERK-2 in vitro. The extracellular-signal regulated 
kinase receives signals from outside of the cell, it is activated via signal cascades that are 
initiated by growth factors, cytokines, UV- and γ-radiation. Once activated, ERK translocates 
and thus carries the signal from the cell surface into the nucleus, where it is known to 
influence gene transcription by phosphorylation of transcription factors. By this way, the cell 
reacts to environmental signals [183]. Interestingly, ERK activation itself within the SCN 
underlies a circadian rhythmicity, imposing a connection between RORα phosphorylation and 
circadian rhythmicity [204]. However, these data do not provide a clear evidence for 
phosphorylation by ERK as transcriptional activity modulator so far. 
 
RORα4 Sumoylation 
The small-ubiquitine-related modifier (SUMO) is a protein moiety that is ligated to lysine 
residues in a variety of target proteins. It is structurally related to ubiquitine, and the 79 amino 
acids long molecule features a molecular weight of 11 kDa. The addition of SUMO can 
modulate the ability of proteins to interact with their partners, alter their patterns of 
subcellular distribution and control their stability. SUMO influences many different biological 
processes, but recent data suggest that it is particularly important in the regulation of gene 
transcription. Several steroid-, e. g. the PR [236], as well as non-steroid nuclear receptors 
have recently been shown to be sumoylated. Reports have shown that sumoylation of PPARγ 
results  in an increased protein turnover rate [237]. Bmal1 shows a circadian pattern of Discussion 
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sumoylation that parallels its activation, sumoylation stabilizes Bmal1 protein and is 
necessary for Bmal1 rhythmicity [181,238].  
RORα4 sumoylation was taken into account, because Western Blots of RORα4 protein 
showed three distinct bands differing in approx. 10 kDa molecular weight. The RORα4 amino 
acid sequence contains four potential SUMO recognition motifs, but mutation of this motif 
did not eliminate one of the three distinct bands observed on an immunoblot obtained from 
transfected HeLa cells. According to Tojo et al. [238], SUMO1 was cloned from cDNA and 
cotransfected with RORα4. However, no additional bands were detected after cotransfection 
in HeLa cells. Altogether, an evidence for RORα4 modification by sumoylation is not 
apparent. 
 
RORα4 protein cleavage 
There are several hints for a RORα4 protein cleavage in transfected HeLa cells. 
Immunoblotting of RORα4 and two truncation mutants revealed additional bands that were 
not detected after transfection of the empty vectors. The monoclonal anti-ROR antibody clone 
6E8 detected the fragment containing the first amino acids of the hinge region (aa 83-105, 
CTE), whereas the polyclonal antibody from Santa Cruz, recognizing epitopes within the 
ligand binding domain and/or the N-terminal part of the hinge domain, detected the other 
fragment of RORα. The 55 kDa-sized RORα4 wild-type is cleaved into two fragments of 
approx. 20 and 35 kDa, the 82 kDa-sized EGFP-RORα4 in 47 and 35 kDa and the 72 kDa-
sized EGFP-HI-LBD1 in 37 and 35 kDa. The mass of cleavage fragments and their detection 
by the respective antibodies, suggest a cleavage site within the first third of the hinge domain. 
Further investigations will be necessary to reveal the cleavage mechanism and if the cleavage 
has a consequence on RORα4 signaling. 
 Summary 
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6 SUMMARY 
 
The retinoic acid related orphan receptor α (RORα) regulates the expression of various target 
genes by binding to specific response elements in their promoter region. RORα is an 
interesting pharmaceutical target since it positively affects several pathophysiological 
processes of clinical relevance. RORα enhances the expression of Apo-AI protein, the major 
constituent of HDL, which is responsible for the cholesterol transportation. RORα notably 
contributes to the bone mineralization and generation of the extracellular bone matrix, 
demonstrating its involvement in osteoporosis, and by up-regulating the gene for IκBα, RORα 
has anti-inflammatory effects. Moreover, RORα is necessary for cerebellar development and 
the maintenance of the mammalian day-night periodicity governed by the core-clock within 
the suprachiasmatic nuclei. RORα receptors have been reported to bind cholesterol, 
melatonin, or to function ligand-independent. By monomeric binding to the recognition motif 
AGGTCA preceded by an A/T-rich sequence (ROR response element, RORE), RORα 
constitutively activates gene transcription. However, RORα activity is passively suppressed 
by its opponents RevErbα and RevErbβ, which both bind to the same target sequence. 
 
A method for overexpression and purification of RORα4 in E. coli was established, 
facilitating the production of mg amounts of pure RORα4 protein within three days. Although 
RORα4 was expressed in insoluble and inactive inclusion bodies, the protein could be 
solubilized with 6 M guanidine and refolded into its native conformation. This was obtained 
by dialysis against different buffers of descending guanidine content and with help of the 
adjuvant L-arginine. Despite this rather complex operation, a final protein concentration of 
300-400 µg/ml could be achieved. This solution could be stored at –70°C over months 
without lost of quality. 
The functionality of refolded RORα4 protein was proved by performing an electrophoretic 
mobility shift assay, where RORα4 binding to a double-stranded, monomeric ROR response 
element was demonstrated. RORα4 was fused to a N-terminal polyhistidine tag which 
allowed the further purification by Nickel affinity chromatography. 
Because of the obvious sequence homology between RORα and its opponent RevErbα, it was 
possible to apply the RORα4 overexpression and purification protocol for RevErbα protein 
production. Although the conditions might be further optimized, the protein was produced in Summary 
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an acceptable quality and passable quantity by inclusion body separation and protein 
refolding.  
In addition to that, an anti-RORα antibody was generated by immunization of Balb/c mice 
with overexpressed protein. Antibody clone 6E8 showed high specificity and sensitivity and 
could be used for detecting of both denatured and native RORα4 protein. The antibody 
epitope was identified by immunoblotting of various RORα4 truncation mutants, and amino 
acids 83-105 of human RORα4 emerged as necessary for antibody recognition. These amino 
acids lie within the hinge domain which is conserved throughout all RORα1-α4 isoforms, 
facilitating the detection of all RORα isoforms by antibody clone 6E8. 
Both the overexpression method for RORα and RevErbα, and the anti-RORα antibody were 
important tools for subsequent investigations on RORα signaling. 
Since the activity of many nuclear receptors is regulated by phosphorylation, RORα4 was 
screened for phosphorylating kinases. For this purpose, RORα4 was polymerized into a gel 
matrix, refolded within this matrix and subjected to in-gel phosphorylation with kinases 
provided from cell lysates that were separated over the gel. This experiment revealed a 
RORα4 phosphorylating kinase with an approx. molecular weight of 40 kDa, which could be 
identified as extracellular-signal regulated kinase (ERK).  
ERK can be activated over signal cascades that are initiated by e. g. growth factors, cytokines, 
UV- and γ-radiation. Once activated, ERK translocates and thus carries the signal from the 
cell surface into the nucleus, where it is known to influence gene transcription by 
phosphorylation of transcription factors. In this way, the cell reacts on requirements of the 
environment.  
ERK phosphorylated RORα4 at Thr-128 in vitro. Mutation of Thr-128 to Ala completely 
suppressed RORα4 phosphorylation by ERK. The T128A mutant revealed an increased 
transcriptional activity in a reporter gene assay, and in competition experiments with 
RevErbα, RORα4-T128A was more resistant to replacement by RevErbα on the RORE then 
the wild-type. However, there is little evidence that the lack of phosphorylation contributes to 
the stronger DNA binding affinity of the T128A mutant. Physical exchange of Thr-128 to Val 
or Ile also increased RORα4 transcriptional activity, whereas mutation to Arg led to an 
attenuation. Two phosphomimetic mutants were generated, T128D and T128E, however, their 
activities ranged between that of wild-type and RORα4-T128A. Nevertheless, these results 
suggest that residue 128 is a sensitive site that influences RORα4 DNA binding affinity. 
Unfortunately, it was not possible to influence the DNA binding affinity in an electrophoretic 
mobility shift assay by phosphorylation of RORα4 in vitro. Cotransfection of a constitutive Summary 
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active as well as a dominant negative form of MEK1, the ERK activating kinase, did not 
influence the activities of RORα4 wild type or mutants. 
Confocal laser scan microscopy of EGFP-fused RORα4 mutants in HeLa and HEK293 cells 
revealed that the subcellular distribution pattern is modulated neither by mutation of Thr-128, 
nor incubation with the kinase activating substance phorbol 12-myristate 13-acetate (PMA). 
RORα4 sumoylation as a further posttranslational modification was taken into account, 
because Western Blots of transfected HeLa cells showed three distinct RORα4 bands differing 
in approx. 10 kDa molecular weight. Generally, addition of SUMO (small-ubiquitine-related 
modifier) to nuclear receptors can modulate their ability to interact with their partners, alter 
their patterns of subcellular distribution and control their stability. The RORα4 amino acid 
sequence contains four potential SUMO recognition motifs, but mutation of this motif did not 
eliminate one of the three distinct RORα4 bands observed on an immunoblot obtained from 
transfected HeLa cells. Moreover, cotransfection of SUMO1 with RORα4 gave no 
additionally detected bands. Altogether, an evidence for RORα4 modification by sumoylation 
is not immediately apparent. 
In addition to that, there are several hints for a RORα4 protein cleavage in transfected HeLa 
cells. Immunoblotting of RORα4 and two truncation mutants revealed two additional bands 
that were not detected after transfection of the empty vectors. The mass of cleavage fragments 
and their respective detection by two different anti-RORα antibodies suggest a cleavage site 
within the first third of the hinge domain. Further investigations will be necessary to reveal 
the cleavage mechanism and if the cleavage has a consequence on RORα4 signaling. 
 
In analogy to the experiments performed with RORα, RevErbα was shown to be target of in 
vitro phosphorylation by ERK. The amino acid sequence of RevErbα revealed 18 putative 
consensus motifs, but the actual phosphorylation site and the physiological relevance still 
remain to be clarified. First experiments on the physiological relevance of this 
phosphorylation by incubation of a RORα4-RevErbα interplay on the RORE in a luciferase 
assay system with PMA, gave no answers so far.  
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7 ZUSAMMENFASSUNG 
 
Der Retinoic Acid Related Orphan Recepor α (RORα) ist ein nukleärer Rezeptor, der die 
Expression verschiedener Targetgene reguliert, indem er an spezifische Erkennungssequenzen 
in deren Promotorbereiche bindet. Pharmazeutisches Interesse erweckt RORα, weil es einige 
klinisch relevante pathophysiologische Prozesse positiv beeinflusst. Anti-atherosklerotische 
Eigenschaften werden RORα nachgesagt, da es die Expression von Apo-AI aktiviert, welches 
den Hauptbestandteil des Cholesterol-transportierenden HDLs darstellt. Durch die Ver-
stärkung der Knochenmineralisierung und dem Aufbau der extrazellulären Knochenmatrix 
kann RORα einer Osteoporose entgegenwirken. Außerdem wirkt RORα anti-inflammatorisch, 
da es die Expression von IκBα verstärkt und damit den NF-κB-Signalweg hemmt. Des 
weiteren ist RORα an der Gehirnentwicklung und an der Aufrechterhaltung des Tag-Nacht-
Rhythmus, der bei Säugetieren in den suprachiasmatischen Nuclei erzeugt wird, beteiligt. Bei 
Kristallisationsexperimenten wurde Cholesterin in der Ligandenbindungstasche von RORα 
gefunden, und es wird diskutiert, ob auch Melatonin mit dem nukleären Rezeptor interagiert. 
Allerdings gibt es ebenso Studien die beweisen, dass RORα auch ohne Ligand in der 
aktivierten Konformation vorliegt. Durch monomere Bindung an das DNA-Erkennungsmotiv 
AGGTCA (ROR response element, RORE), welchem eine A/T-reiche Sequenz vorangeht, 
kann RORα konstitutiv aktivierend wirken. Allerdings kann diese Aktivität durch die 
Gegenspieler RevErbα und RevErbβ passiv reprimiert werden, da jene die gleichen Motive 
erkennen und RORα aus seiner Bindung verdrängen können. 
 
Es wurde eine Methode zur Überexpression und Aufreinigung von RORα4 in E. coli etabliert, 
mit der man innerhalb von 3 Teigen reines Protein in mg-Mengen erhalten kann. Obwohl 
RORα4 in E. coli in Form von unlöslichen und inaktiven Einschlusskörpern (Inclusion 
Bodies) produziert wurde, konnten diese in 6 M Guanidin gelöst und das Protein in seine 
native Form rückgefaltet werden. Dies wurde durch Dialyse gegen verschiedene Puffer mit 
absteigenden Guanidinkonzentrationen erreicht, zusätzlich wurde L-Arginin als Hilfsstoff zur 
Stabilisierung der Faltungsintermediate eingesetzt. Obwohl das Rückfaltungsverfahren relativ 
aufwändig war und zu Beginn des Prozesses nur sehr geringe Proteinkonzentrationen 
eingesetzt werden mussten, wurden am Ende Lösungen mit 200-300 µg/ml RORα4 erreicht. 
Das auf diese Weise rückgefaltete Protein konnte bei –70°C über mehrere Monate gelagert 
werden, ohne dass ein Qualitätsverlust zu verzeichnen war. Zusammenfassung 
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Die Funktionalität des rückgefalteten RORα4-Rezeptors wurde anhand von in vitro DNA-
Bindungsstudien bewiesen, in denen gezeigt werden konnte, dass das Protein an ein 
doppelsträngiges Oligonukleotid, welches ein monomeres RORE enthielt, bindet. 
An das Protein wurde N-terminal ein Polyhistidin-Rest angebracht, über den RORα4 mittels 
Nickel-Affinitätschromatographie noch weiter aufgereinigt werden konnte. Je Liter E. coli-
Kultur konnten auf diese Weise 16-20 mg RORα4 in einer Reinheit von 85% gewonnen 
werden. 
Bedingt durch die hohe Sequenzhomologie zwischen RORα und RevErbα, konnte die 
Methode zur Überexpression und Aufreinigung von RORα direkt auf RevErbα übertragen 
werden. Die Konditionen erwiesen sich zwar als optimierungsfähig, dennoch konnte durch 
Inclusion-Body-Separation, Lösung in 6 M Guanidin und Proteinrückfaltung, reines, 
funktionsfähiges RevErbα gewonnen werden.  
Durch Immunisierung von Balb/c-Mäusen mit überexprimiertem RORα konnte ein Anti-
RORα-Antikörper generiert werden. Acht Injektionen über einen Zeitraum von 6 Monaten 
reichten aus, um die Bildung von Antikörpern zu provozieren. Nachdem einzelne 
Mauslymphozyten mit NS-1-Zellen fusioniert wurden, konnten aus der Hybridomzelllinie 
6E8 Anti-RORα-Antikörper gewonnen werden, die besonders hohe Spezifität und Sensitivität 
aufwiesen und zur Detektion sowohl von nativem, als auch von denaturiertem Protein 
verwendet werden konnten. Das Antikörper-Epitop wurde durch Immunoblotting von 
verschiedenen, verkürzten RORα4-Mutanten bestimmt, wobei sich die Aminosäuren 83-105 
von humanem RORα4 als detektierte Region herausstellten. Dieser Bereich liegt innerhalb der 
Hinge-Domäne, die bei allen RORα1-4-Isoformen in identischer Sequenz vorliegt und daher 
alle 4 Isoformen mit Klon 6E8 detektierbar sein müssten. 
Sowohl die Überexpressionsmethode für RORα bzw. RevErbα, als auch der Anti-RORα-
Antikörper stellten wichtige Werkzeuge dar, die sich für weitere Versuche rund um den 
nukleären Rezeptor RORα4 als unerlässlich erwiesen. 
 
Die Aktivität vieler nukleärer Rezeptoren, sowohl die der Steroid- als auch die der Non-
Steroidrezeptoren, wird durch Phosphorylierung reguliert. Diese Art der posttranslationalen 
Modifikation beeinflusst die Wechselwirkung mit anderen Proteinen, Liganden oder der DNA 
selbst. Auch kann die Lokalisation innerhalb der Zelle oder die Proteinstabilität verändert 
werden. Eine Phosphorylierung kann sowohl aktivierende als auch inhibierende Wirkung 
zeigen. Zusammenfassung 
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Auf der Suche nach Kinasen die RORα4 phosphorylieren, wurde RORα4-Protein kovalent in 
eine SDS-Polyacrylamid-Gelmatrix einpolymerisiert, Zelllysate mit aktivierten Kinasen über 
dieses Gel aufgetrennt und die Proteine innerhalb der Gelmatrix rückgefaltet. Während der 
Inkubation dieses Gels in radioaktivem [γ-
32P]-ATP, konnten die aufgetrennten Kinasen das 
im Gel einpolymerisierte RORα4 phosphorylieren. Durch dieses Experiment wurde eine 
Kinase mit ungefährem Molekulargewicht von 40 kDa entdeckt, die RORα4 phosphorylieren 
konnte und schließlich als ERK (extracellular-signal regulated kinase) identifiziert wurde. 
ERK gehört zu der Familie der MAPK (mitogen activated protein kinases), die sich durch 
extrazelluläre Signale aktivieren lassen. ERK wird u. a. durch Wachstumsfaktoren, Zytokine 
und UV- oder γ-Strahlung aktiviert. Die aktivierte ERK transloziert zum Zellkern und kann 
dort verschiedene nukleäre Rezeptoren phosphorylieren. Auf diese Weise ist ERK in der 
Lage, den Stoffwechsel der Zelle an die Anforderungen der Zellumgebung anzupassen. 
In in vitro-Versuchen wurde Thr-128 des RORα4-Rezeptors als ERK-Phosphorylierungsstelle 
bestimmt. Die Mutation von Thr-128 zu Ala verstärkte die Transkriptionsaktivität von 
RORα4 im Reportergenassay, der mit Hilfe von zwei unterschiedlichen Promotorkonstrukten 
durchgeführt wurde. Der REa23-Promoter enthält drei RORE, die kurz vor einen 
Thymidinkinasepromotor geschaltet wurden. Das zweite Konstrukt enthält an der gleichen 
Stelle den humanen Bmal1-Promoter, der für die Generation des zirkadianen Rhythmus im 
suprachiasmatischen Nucleus verantwortlich ist. Auf beiden Promotoren wirkt RORα4 
aktivierend, während RevErbα die RORα4-vermittelte Transkriptionsaktivität durch 
Verdrängung des Rezeptors vom RORE aufhebt. In Kompetitionsexperimenten mit dem 
Gegenspieler RevErbα ließ sich RORα-T128A auf beiden Promotoren weniger leicht vom 
RORE verdrängen als der Wildtyp. Allerdings gibt es wenige Hinweise darauf, dass die 
verstärkte Aktivität der T128A-Mutante tatsächlich auf die fehlende Phosphorylierung 
zurückzuführen ist. Mutation von Thr-128 zu Val oder Ile verstärkte ebenso die Aktivität des 
Rezeptors, während Austausch zum positiv geladenen Arg sie verringerte. Es wurden zwei 
phosphomimetische Mutanten erzeugt, indem Thr-128 gegen Asp oder Glu ausgetauscht 
wurde, die von der Struktur her einem phosphoryliertem Thr ähneln. Allerdings lag die 
Aktivität der beiden phosphomimetischen Mutanten zwischen den Aktivitäten von Wildtyp 
und Ala-Mutante. Diese Ergebnisse zeigen, dass die Aminosäure an Position 128 eine 
sensitive Stelle ist, deren Konstitution Einfluss auf die DNA-Bindungseigenschaften des 
RORα4-Rezeptors nimmt. Thr-128 ist in der Nähe der Carboxy-terminalen Extension (CTE) 
lokalisiert, von der gezeigt wurde, dass sie für die monomere Bindung von RORα an das 
RORE essentiell ist. Es war jedoch nicht möglich, die DNA-Bindungseigenschaften von Zusammenfassung 
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RORα4 in einem EMSA (electrophoretic mobility shift assay) durch vorherige in vitro 
Phosphorylierung zu verändern. 
Verschiedene Versuche wurden unternommen, um die zelluläre ERK von transfizierten HeLa-
Zellen zu aktivieren. Inkubation mit dem unspezifischen Kinaseaktivator Phorbol-12-
myristat-13-acetat (PMA) führte zu einer Verringerung der Aktivität von RORα4, die durch 
den spezifischen Inhibitor der ERK-Aktivierung U0126 wieder aufgehoben werden konnte. 
Dieser Effekt wurde allerdings nicht durch eine ERK-Phosphorylierung verursacht, denn die 
T128A-Mutante ließ sich in ähnlicher Weise von PMA und U0126 manipulieren. 
MEK1 phosphoryliert und aktiviert somit ERK. Eine konstitutiv aktive Form von MEK1 führt 
zu einer Daueraktivierung von ERK, wogegen eine dominant negative MEK1 die Aktivierung 
verhindert. Cotransfektion von einer konstitutiv aktiven, sowie einer dominant negativen 
MEK1 zusammen mit entweder dem RORα4 Wildtyp oder der T128A-Mutante veränderte 
deren Transkriptionsaktivitäten nicht. 
Der Einfluss der Phosphorylierung auf die subzellulare Lokalisation von RORα4 wurde durch 
konfokale Laserscan-Mikroskopie von EGFP-getaggtem RORα4 und Mutanten in 
transfizierten HeLa und HEK293 untersucht. Hinsichtlich der Verteilung innerhalb der Zelle 
konnten keine Unterschiede beobachtet werden, auch Inkubation mit PMA hatte keinen Effekt 
auf die zelluläre Lokalisation der Proteine. 
Für den Wildtyp und die T128A-Mutante wurden Studien zur Proteinstabilität durchgeführt. 
Frühere Ergebnisse zeigten, dass RORα erst ubiquitinyliert und anschließend durch das 
Proteasom abgebaut wird. Da der Proteasominhibitor MG-132 stets zu einer verringerten 
Aktivität führte wurde spekuliert, ob der Abbau durch das Proteasom für den Start der 
Transkription essentiell ist. Inkubation von transfizierten HeLa-Zellen mit MG-132 
beeinflusste die T128A-Mutante jedoch in gleichem Maße wie den Wildtyp. Auch 
Proteinstabilitätsexperimente über einen Zeitraum von 6 Tagen zeigten keine Unterschiede 
zwischen Ala-Mutante und Wildtyp. 
Neben der Phosphorylierung wurden auch die Möglichkeit weiterer posttranslationaler 
Modifikationen untersucht. Western Blots von transfizierten HeLa-Zellen zeigten RORα4 als 
eine Ansammlung von 3 Banden, die sich in einem Molekulargewicht von ca. 10 kDa 
unterschieden. Daher wurde eine Modifikation durch Sumoylierung in Betracht gezogen. Das 
Anfügen eines SUMO-Restes (small ubiquitine-related modifier) an einen nukleären Rezeptor 
kann zu vielerlei Effekten führen, z. B. kann die Interaktion mit anderen Proteinen beeinflusst 
werden, ebenso die zelluläre Verteilung oder die Proteinstabilität. Die Primärsequenz von 
RORα4 weist 4 potentielle Sumoylierungsstellen auf, die alle einzeln mutiert wurden. Zusammenfassung 
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Allerdings führte keine der Mutationen zum Verschwinden einer der drei Banden, die 
typischerweise für RORα4 in transfizierten HeLa-Zellen gefunden werden. Auch eine 
Cotransfektion eines SUMO1-Überexpressionsvektors führte zu keiner additiv detektierten 
Bande. Bisher liegen demnach keine Hinweise darauf vor, dass RORα4 sumoyliert wird. 
Eine weitere posttranslationale Modifikation könnte eine Spaltung von RORα4 sein. Auf 
Blots von transfizierten HeLa-Zellen waren neben den drei erwähnten Banden zwei weitere 
Banden zu erkennen, deren Molekulargewichtssumme stets das Molekulargewicht des 
Gesamtproteins ergaben. Dies konnte außer für den RORα4-Wildtyp für zwei weitere, 
verkürzte RORα4-Formen nach Transfektion in HeLa-Zellen beobachtet werden. 
Transfektion eines leeren Expressionsvektors hingegen zeigte keiner dieser detektierten 
Banden. Manche Fragmente ließen sich nur mit dem monoklonalen anti-RORα-Antikörper 
6E8 detektieren, andere hingegen nur mit dem polyklonalen RORα-Antikörper der Firma 
Santa Cruz. Anhand der Fragmentgrößen und der Detektion durch einen bestimmten 
Antikörper ließ sich das erste Drittel der Hinge-Domäne als ungefähre Schnittstelle 
berechnen. Weitere Experimente sind notwendig, um den Spaltungsmechanismus und die 
genaue Stelle zu untersuchen. 
 
In Analogie zu den Experimenten die mit RORα durchgeführt wurden, konnte auch für den 
Gegenspieler RevErbα eine Phosphorylierung durch ERK nachgewiesen werden. Die 
Aminosäuresequenz von RevErbα enthält 18 potentielle ERK-Phosphorylierungsmotive, die 
tatsächliche Stelle ist allerdings noch nicht bekannt. Erste Studien zur physiologischen 
Relevanz der RevErbα-Phosphorylierung wurden vorgenommen, dabei wurde ein RORα4-
RevErbα Kompetitionsexperiment im Reportergen-Assay mit PMA inkubiert. Allerdings 
konnte bisher keine Auswirkung der unspezifischen Kinasenaktivierung auf die Aktivität von 
RevErbα gezeigt werden. 
 
 
 
 
 Abbreviations 
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8 ABBREVIATIONS 
 
A  alanine 
AA  arachidonic acid 
ACTR  acetyl transferase 
AF-1/2  activation function 1/2 
AIB  amplified in breast cancer 
AKBA  O-acetyl 11-keto boswellic acid 
Ala  alanine 
Apo  apolipoprotein 
AR  androgen receptor 
Arg  arginine 
Asp  aspartic acid 
ATP  adenosine triphosphate 
Bcip  5-bromo 4-chloro 3-indolylphosphate 
Bmal  brain-muscle-Arnt-like protein 
bp  base pairs 
BSA  bovine serum albumin 
ca  constitutive active 
CaMK  calcium-calmodulin dependent kinase 
cAMP  cyclic adenosine monophosphate 
CBP  CREB-binding protein 
cdk  cyclin-dependent kinase 
cDNA  coding DNA 
cds  coding sequence 
CKIε  casein kinase I epsilon 
CMV  cytomegalie virus 
COX  cyclooxygenase 
Cry  cryptochrome 
CTE  C-terminal extension 
D  aspartic acid 
dbcAMP  di-buturyl-cAMP 
DBD  DNA binding domain 
D-MEM  Dulbecco´s modified eagle medium 
DMSO  dimethylsulfoxide 
dn  dominant negative 
DRIP  VDR-interacting protein 
DTT  dithiothreitol 
E  glutamic acid 
EDTA  ethylenediaminetetraacetic acid 
EGFP  enhanced green fluorescent protein 
EGTA  ethylene glycol-bis(2-aminoethylether)-N,N,N´,N´-tetraacetic acid 
ELISA  enzyme-linked immunosorbent assay 
EMSA  electrophoretic mobility shift assay 
ER  estrogen receptor 
ERK  extracellular signal-regulated kinase 
FASPS  familiar advanced sleep-phase syndrome 
FCS  fetal calf serum 
fMLP  N-formyl-Met-Leu-Phe Abbreviations 
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Glu  glutamic acid 
GPCR  G protein coupled receptor 
GR  glucocorticoid receptor 
GRIP  GR-interacting protein 
GSK3β  glycogen synthase kinase 3 beta 
GST  glutathione-S-transferase 
H  helix 
hASMC  human aortic smooth muscle cells 
HDL  high density lipoprotein 
HEK  human embryonic kidney cells 
HeLa  epithelial cells derived from cervix carcinoma 
HEPES  4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
HepG2  human hepatoma cell line 
hr  hairless 
HRE  hormone response element 
HUVEC  human umbilical vein endothelial cells 
IL  interleukin 
Ile  isoleucine 
i. p.  intraperitoneal 
IPTG  isopropyl-β-D-thiogalactopyranoside 
IR  infrared 
IκBα  NF-κB inhibiting protein alpha 
JNK  c-jun NH2-terminal kinase 
ko  knockout 
LBD  ligand binding domain 
LPS  lipoplysaccharide 
LU  light units 
MAPK   mitogen activated protein kinase 
MBP  myelin basic protein 
MCF-7  human mammary gland epithelial cells 
MEK  MAPK kinase 
MEKK  MAPK kinase kinase 
MT  melatonin receptor 
NBT  nitroblue-tetrazolium chloride 
NCoR  nuclear receptor corepressor 
NF-κB  nuclear factor kappa B 
NGFI-B  NGF induced clone B 
NMDA  N-methyl-D-aspartate 
PAF  platelet activating factor 
PBP  PPAR-binding protein 
PBS  phosphate buffered saline 
Pcp  Purkinje cell specific protein 
PCR  polymerase chain reaction 
PEG  polyethylene glycol 
Per  period 
PKA  protein kinase A 
PKC  protein kinase C 
PMA  phorbol 12-myristate 13-acetate 
PMNL  polymorphonuclear leukocytes 
PMSF  phenylmethanesulfonyl fluoride 
PPAR  peroxisome proliferator activated receptor Abbreviations 
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PR  progesterone receptor 
PRMT  protein arginine N-methyltransferase 
PVDF  polyvinylidendifluoride 
RAC  receptor-associated coactivator 
RAR  retinoic acid receptor 
RE  response element 
RevErb  reverse erbA receptor 
RLU  relative light units 
ROR  retinoic acid related orphan receptor 
RORE  ROR response element 
RXR  retinoid X receptor 
RZR  retinoid Z receptor 
SA  sodium arsenite 
SCN  suprachiasmatic nuclei 
SCOP  SCN circadian oscillatory protein 
SDS  sodium dodecylsulfate 
SDS-PAGE  SDS-polyacrylamide gel electrophoresis 
SEAP  secreted alkaline phosphatase 
SF/FTZ-F  steroidogenic factor/Fushi Tarazu factor 
sg  staggerer 
SHP  small heterodimeric partner 
SMRT  silencing mediator of retinoid and thyroid receptors 
SRC  steroid receptor coactivator 
STI  soybean trypsin inhibitor 
SUMO  small ubiquitine-related modifier 
TFIIH  transcription/DNA repair factor II 
TIF  transcriptional intermediary factor 
TK  thymidin kinase 
TNFα  tumor necrosis factor 
TR  thyroid hormone receptor 
TRAM  TR activator molecule 
TRAP  TR-associated protein 
Val  valine 
VDR  vitamin D receptor 
WB  Western Blot References 
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10 APPENDIX 
 
Antibody 
(developed in) 
Purchased  
from 
Working 
dilution  Buffer 
anti-RORα (goat)  Santa Cruz  2 µg/ml  TBS+0.3% Tween 20+0.05% 
NaN3 
anti-RORα (mouse)  -  2 µg/ml  TBS+0.3% Tween 20+0.05% 
NaN3 
anti-RevErbα   US Biologicals  EMSA: pure  - 
anti-RevErbα   Perseus 
Proteomics 
WB: 1 µg/ml TBS+0.3% Tween 20+0.05% 
NaN3 
anti-Bmal1 (rabbit, 
antiserum) 
Abcam 1:100  PBS+0.05%  NaN3 
anti-GFP (mouse, 
antiserum) 
Sigma  1:2000  TBS+0.3% Tween 20+0.05% 
NaN3 
anti-MEK1  QED Bioscience  1 µg/ml  PBS+0.05% NaN3 
anti-ERK (rabbit)  New England 
Biolabs 
1:1000  5% low-fat milk powder in 
PBS+0.3% Tween 20 
anti-P-ERK (mouse)  New England 
Biolabs 
1:1000  5% low-fat milk powder in 
PBS+0.3% Tween 20 
anti-rabbit (goat, 
alkaline phosphatase 
conjugated) 
Sigma  1:1000  5% low-fat milk powder in TBS 
anti-mouse (goat, 
alkaline phosphatase 
conjugated) 
Sigma  1:1000  5% low-fat milk powder in TBS 
anti-goat (rabbit, 
alkaline phosphatase 
conjugated) 
Sigma  1:1000  5% low-fat milk powder in TBS 
 
Table 10.1: Antibodies used for Immunoblotting or Electrophoretic Mobility Shift Assay. 
 
 
 
 
Table 10.2: Substances used for incubation of transfected HeLa cells. 
 
 
 
Substance  Purchased from  Working dilution 
U0126  Alexis  10 mM in DMSO 
PMA  Sigma  100 µM in DMSO 
MG-132  Calbiochem  10 mM in DMSO Appendix 
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Mutant  Primer   Sequence (5´ to 3´) 
T128A  T128A-for 
T128A-rev 
GTTGTAGGTGGGCGCCAGCGGCTCAGC 
GCTGAGCCGCTGGCGCCCACCTACAAC 
T153A  T153A-for 
T153A-rev 
CATTGACGGGCACGCACCTGAGG 
CCTCAGGTGCGTGCCCGTCAATG  
S173A  S173A-for 
S173A-rev 
CATACAGCCTGCACCAGACCAG 
CTGGTCTGGTGCAGGCTGTATG 
T193A  T193A-for 
T193A-rev  
CAATATGTGACTACGCCCCAGCATCAG 
CTGATGCTGGGGCGTAGTCACATATTG 
S210A  S210A-for 
S210A-rev 
GACACAGTTGGTGCAGTCTCGCCGTTG 
CAACGGCGAGACTGCACCAACTGTGTC 
S332A  S332A-for 
S332A-rev 
CGTCGGGTGCGGCATACTTC 
GAAGTATGCCGCACCCGACG 
T128D  T128D-for 
T128D-rev 
TGAGCCGCTGGATCCCACCTAC 
GTAGGTGGGATCCAGCGGCTCA 
T128E  T128E–for 
T128E–rev 
TGAGCCGCTGGAGCCCACCTAC 
GTAGGTGGGCTCCAGCGGCTCA 
 
Table 10.3: Primers used for site directed mutagenesis on pET28a-RORα4 or pSG5-RORα4 in order to 
mutate putative ERK phosphorylation sites. 
 
 
 
 
Table 10.4: Primers used for cloning of the Bmal1-promoter and Bmal1 protein isoforms A and B from 
genomic DNA and cDNA of Mono Mac 6 cells, respectively. 
 
 
Fragment  Primer   Sequence (5´ to 3´) 
Bmal1-
prom 
Bmal1-MluI-for 
Bmal1-XhoI-rev 
GATAACGCGTCCCAGAGAAGAGGGACATCCCGG 
GATACTCGAGCGCGCCCGCACTCGGATCCCGC 
Bmal1- 
iso A 
B_A_EcoRI-for 
B_BglII-rev 
TAGAGAATTCATGGCAGACCAGAGAATGGAC 
TAGGAGATCTTTACAGCGGCCATGGCAAGTC 
Bmal1- 
iso B 
B_B_EcoRI-for 
B_BglII-rev 
TAGAGAATTCATGATTAATATAGAAAGCATGGACACAG
TAGGAGATCTTTACAGCGGCCATGGCAAGTC Appendix 
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Table 10.5: Primers used for the generation of RORα truncation mutants for determination of anti-RORα 
antibody epitope. 
 
 
 
Mutant  Primer   Sequence (5´ to 3´) 
K89A  K89A-for 
K89A-rev 
GATGCTGTAGCATTTGGCCGAATG 
CATTCGGCCAAATGCTACAGCATC 
K185A  K185A-for 
K185A-rev 
CAATGGAATCGCTCCAGAACCAATATG 
CATATTGGTTCTGGAGCGATTCCATTG 
K302A  K302A-for 
K302A-rev 
CAAATTGTGCTTCTAGCTGCAGGTTCTC 
GAGAACCTGCAGCTAGAAGCACAATTTG 
T193A  K386A-for 
K386A-rev 
GAAAAGGTAGCAATTGAAAAACTGCAACAG 
CTGTTGCAGTTTTTCAATTGCTACCTTTTC 
 
Table 10.6: Primers used for site directed mutagenesis on pSG5-RORα4 in order to mutate putative 
sumoylation motifs. 
 
 
 
Primer   Sequence (5´ to 3´) 
SUMO1-SpeI-for 
SUMO1-HindIII-rev 
GCCACCACTAGTATGTCTGACCAGGAGGCAAAACCTTC 
GCCACCAAGCTTAACTGTTGAATGACCCCCCGTTTG 
 
Table 10.7: Primers used for cloning of SUMO1 on cDNA of Mono Mac 6 cells. 
 
 
Fragment  Primer   Sequence (5´ to 3´) 
HI-LBD-1  HI-LBD-1-
HindIII-for  GCTCAAGCTTGTCTCGAGATGCTGTAAAATTTGGC 
HI-LBD-2  HI-LBD-2-
HindIII-for  GCTCAAGCTTGCAGAAACACCGGATGCAGCAG 
HI-LBD-3  HI-LBD-3-
HindIII-for  GCTCAAGCTTGACGCCCACCTACAACATCTCG 
HI-LBD-4  HI-LBD-4-
HindIII-for  GCTCAAGCTTGGACGGGCACACCCCTGAGG 
HI-LBD-5  HI-LBD-5-
HindIII-for  GCTCAAGCTTGCCTTCCCCAGACCAGTCAGGTC 
HI-LBD-6  HI-LBD-6-
HindIII-for  GCTCAAGCTTGCCAGCATCAGGCTTCTTTCCC 
HI-LBD-1-6  HI-LBD-
Acc65l-rev  ATCTGGTACCTTACAGCCATGAGCGATCTGCTG Appendix 
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Fragment  Primer   Sequence (5´ to 3´) 
MEK1-481  MEK1-481-HindIII-for
MEK1-481-EcoRV-rev
ACTTAAGCTTATGCCCAAGAAGAAGCCGAC 
GTTCAGGAATTCTTCCAGCTTTC 
MEK1-701  MEK1-701EcoRV-for 
MEK1-701XhoI-rev 
GAAAGCTGGAAGAATTCCTGAAC 
TAGACTCGAGTTAGACGCCAGCAGCATGGG 
 
Table 10.8: Primers used for cloning of MEK1 on cDNA of Mono Mac 6 cells. 
 
 
 
Mutant  Primer   Sequence (5´ to 3´) 
MEK1-S218E  S218E-for  
S218E-rev 
GACATCTGGGAGATGGGACTG 
CAGTCCCATCTCCCAGATGTC 
MEK1-S218E-S222D 
= ca-MEK1 
S222D-for 
S222D-rev 
GATGGGACTGGATCTGGTAGAGATG 
CATCTCTACCAGATCCAGTCCCATC 
MEK1-K97M  
= dn-MEK1 
K97M-for 
K97M-rev 
GTCATGGCCAGAATGCTAATTCATC 
GATGAATTAGCATTCTGGCCATGAC 
 
Table 10.9: Primers used for site directed mutagenesis on pSG5-MEK1 in order to generate a constitutive 
active (ca) and a dominant negative (dn) MEK1. 
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